2000 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 -----FORM 10-K/A (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2000 or [\_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THIS SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File No. 000-24657 MANNATECH, INCORPORATED (Exact Name of Registrant as Specified in its Charter) Texas 75-2508900 (State or other Jurisdiction (I.R.S. Employer of Incorporation or Organization) Identification No.) 600 S. Royal Lane, Suite 200 75019 Coppell, Texas (Zip Code) (Address of Principal Executive Offices) Registrant's Telephone Number, including Area Code: (972) 471-7400 Securities Registered Pursuant to Section 12 (b) of the Act: None Securities Registered Pursuant to Section 12 (g) of the Act: Title of each class Name of each exchange on which registered Common Stock, par value \$0.0001 per share Nasdag National Market -----Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [\_] Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [\_] The aggregate market value of the 13,037,642 shares of registrant's voting stock held by non-affiliates of the registrant was \$15,071,514, based on the closing price of the registrant's common stock on the Nasdaq National Market on March 19, 2001 of \$1.156 per share. Documents Incorporated by Reference Mannatech incorporates information required by Part III (Items 10, 11, 12 and 13) of this report by reference to its definitive proxy statement to be filed pursuant to Regulation 14A on or before April 30, 2001.

# TABLE OF CONTENTS

	Page
Special Note Regarding Forward-Looking Statements	1
Part I	
Item 1. Business	2
General	2
Industry Overview	3
Operating Strengths	4
Growth Strategy	5
Products and Product Development	6
Product Distribution System	8
Information Technology and Systems	12
Production and Distribution	12
Government Regulations	13
Competition	17
Employees	17
Item 2. Properties	18
Item 3. Legal Proceedings	18
Item 4. Submission of Matters to a Vote of Security Holders	19
Item 5. Market for Registrant's Common Equity and Related Shareholder	
Matters	19
Item 6. Selected Financial Data	20
Item 7. Management's Discussion and Analysis of Financial Condition and	
Results of Operations	21
Overview	21
Results of Operations	23
Year ended December 31, 2000 compared with the Year ended December 31,	
1999	23
Year ended December 31, 1999 compared with the Year ended December 31,	
1998	25
Seasonality and Selected Quarterly Statements of Operations	27
Liquidity and Capital Resources	29
Impact of Inflation	30
Recent Financial Accounting Standards Board Statements	30
Item 7A. Quantitative and Qualitative Disclosures about Market Risk	31
Item 8. Financial Statements and Supplementary Data	31
Item 9. Changes in and Disagreements with Accountants on Accounting and	
Financial Disclosure	31
Part III	
Item 10. Directors and Executive Officers of the Registrant	32
Item 11. Executive Compensation	32
Item 12. Security Ownership of Certain Beneficial Owners and Management	32
Item 13. Certain Relationships and Related Transactions	32
Part IV	
Item 14. Exhibits, Financial Statement Schedules and Reports on Form 8-	
K	32

Special Note Regarding Forward-Looking Statements

Some of Mannatech's statements under "Business," "Properties," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Quantitative and Qualitative Disclosures about Market Risk," the Notes to Consolidated Financial Statements and elsewhere in this report constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to certain events, risks and uncertainties that may be outside Mannatech's control. Some of these forward-looking statements include statements of:

- . management's plans, objectives and budgets for its future operations and future economic performance;
- . capital budget and future capital requirements;
- . meeting future capital needs;
- realization of any deferred tax assets;
- . the level of future expenditures;
- . impact of foreign currency translations;
- impact of recent accounting pronouncements;
- . the outcome of regulatory and litigation matters; and
- . the assumptions described in this report underlying such forward-looking statements.

Actual results and developments may materially differ from those expressed in or implied by such statements due to a number of factors, including:

- . those described in the context of such forward-looking statements;
- . future product development and manufacturing costs;
- . changes in Mannatech's incentive plans;
- . timely development and acceptance of new products;
- . the markets of Mannatech's domestic and international operations;
- . the impact of competitive products and pricing;
- . the political, social and economic climate in which Mannatech conducts operations; and
- . the risk factors described in other documents and reports filed with the Securities and Exchange Commission.

In some cases, forward-looking statements are identified by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "approximates," "predicts," "potential" or "continue" or the negative of such terms and other comparable terminology.

Although Mannatech believes that the expectations reflected in these forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither Mannatech nor anyone else assumes responsibility for the accuracy and completeness of such statements and is under no duty to update any of the forward-looking statements after the date of this report.

### Item 1. Business

### General

Mannatech, Incorporated, a Texas corporation, develops and sells proprietary nutritional supplements and topical products through a network marketing system. Mannatech operates in a single segment in which it sells its products in the United States, Canada, Australia, the United Kingdom and Japan through a network of approximately 237,000 active associates as of March 8, 2001 compared to approximately 269,000 active associates as of March 9, 2000. An "active" associate is one who has purchased products from Mannatech within the last 12 months.

Mannatech focuses its development efforts primarily in the area of carbohydrate technology by creating its proprietary ingredient, Ambrotose(R) complex, which combines certain naturally occurring sugars required to support optimal cell-to-cell communication. Mannatech's products are primarily based on scientific advances in the emerging field of phytochemistry. This field has identified certain naturally-occurring components of various plants, known as "phytochemicals," which while not essential to sustain life, are believed fundamental for optimal health. Mannatech's products are designed to support various systems and functions of the human body, including:

- . the cell-to-cell communication system;
- . the immune system;
- . the endocrine system;
- the intestinal system; and
- . the dermal system.

Mannatech markets its products exclusively through a network marketing system that it believes is well suited to its products, which emphasize health and nutrition. Mannatech believes network marketing appeals to a broad cross-section of the population, particularly those seeking to supplement family income, start a home-based business or pursue employment opportunities other than conventional, full-time employment, because it allows in-person product education not available through traditional marketing techniques.

Mannatech completed the following during the past 12 months:

- . opened its Japan subsidiary on June 26, 2000;
- closed operations of its Internet website subsidiary Internet Health Group, Inc. - on December 29, 2000;
- . introduced ImmunoStart(TM) Chewables in October 2000;
- . introduced Glyco-Bears(TM), a children's multi-vitamin, in March 2001;
- made various management changes, including hiring a new Chief Executive Officer, new Chief Information Officer and new President of International Operations;
- . appointed two new independent directors to its Board of Directors;
- entered into a separation agreement with its former Chief Operating Officer, and
- . entered into a consulting agreement with its former President to provide various consulting services as the Global Vision Architect.

Since its initial public offering, Mannatech's common stock has traded on the Nasdaq National Market under the symbol "MTEX." Information for each of Mannatech's most recent five fiscal years, with respect to the amounts of net sales, results of operations and identifiable assets is set forth in this report under Item 6.

Mannatech's principal executive offices are located at 600 S. Royal Lane, Suite 200, Coppell, Texas 75019, its telephone number is (972) 471-7400 and its website address is www.mannatech-inc.com. You can contact the Investor Relations department at (972) 471-6512 or IR@mannatech.com. Unless the context states otherwise, the term "Mannatech," "Company," "our," "we," "their" or "its" as used in this report shall mean Mannatech, Incorporated and all of its subsidiaries, collectively.

### Industry Overview

Mannatech believes that the nutritional supplement industry targets two sub-industries: the wellness industry and the sickness or healthcare industry. The sickness or healthcare industry focuses on curing diseases, disorders and trauma whereas the wellness industry focuses on maintaining optimal health. Each sub-industry includes manufacturers and distributors of products that are generally intended to cure the symptom or disease and/or enhance the body's performance and contributes to optimal health and wellness. Nutritional supplements include:

- . vitamins;
- . minerals:
- . dietary supplements;
- . herbs;
- botanicals; and
- . compounds derived from the above.

In recent years, the nutritional supplement industry has experienced substantial growth. Mannatech believes the growth is a result of the following:

- the adoption of the Dietary Supplement Health and Education Act of 1994, which allows vendors of dietary supplements to educate consumers regarding the effects of certain ingredients;
- a widespread and growing interest and awareness among consumers on issues of diet, nutrition and health;
- the continued rise in the introduction of new nutritional products in response to scientific research;
- a boom in exercise and fitness activities, fitness facilities and stress management programs;
- . the world's developed economies and domestic economy that generates discretionary income and created an educated populace;
- aging generations, particularly the baby-boomers, who are willing to purchase products, services and activities that are associated with achieving optimal wellness; and
- . a trend toward preventive health treatments.

According to the 2000 Nutrition Business Journal Annual Industry Survey, global nutrition sales by region for 2000 and expected growth for the industry by region for 2001 and 2002 are as follows:

		Expected Growth Percentage for
Region	(in billions)	•
United States	4.0	8% 8% 7%
Europe		6%
JapanOther regions		6% 7%
Total for all regions	\$137.9 =====	7%

Mannatech believes nutritional supplements are most successful when they are sold primarily through:

- . direct sales organizations;
- mass market retailers, including mass merchandisers, drug stores, supermarkets and discount stores;
- . health food stores; and
- mail order companies.

## Operating Strengths

Mannatech maintains the following business strategy:

- . to develop, maintain and continuously improve its proprietary nutritional supplements, which contain ingredients that are naturallyoccurring, plant-derived and carbohydrate-based. New and existing products should have both health benefits and mass appeal to a general population, that is seeking non-toxic healthcare alternatives;
- . to provide an appealing framework for persons interested in its products to establish a network marketing business; and
- . to broaden its product focus in the nutritional supplement industry from the sickness sub-industry to also include the wellness sub-industry.

Mannatech believes its business strategy will enable it to continue, by capitalizing on the following strengths:

Proprietary Products. Mannatech believes that the discovery and development of products containing certain carbohydrates necessary for optimal health is key in expanding business opportunities for its associates. Mannatech recognized the nutritional need for the eight known monosaccharides in supporting optimal health and believes it offers innovative proprietary products to fulfill this nutritional need. Mannatech filed a patent application on its compound containing certain specific monosaccharides called Ambrotose(R) complex. Mannatech believes inclusion of this compound in its proprietary products is important for two reasons:

- it is a marketing factor that continues to differentiate its products from its competitors; and
- . the limited availability helps drive demand and enable optimal pricing.

Research and Development. Mannatech believes that its research and development facilities and experienced personnel will allow it to develop and market additional proprietary products. Mannatech's research and development efforts are led by scientists with significant years of experience designing products based on carbohydrate technology. Mannatech's technologically advanced laboratory is equipped with gas and liquid chromatographs and mass spectrometers, which are used to:

- . maintain quality standards;
- . support research and development in the area of new herbal complexes;
- help support the development of both new and existing products.

To complement its in-house staff and facilities, Mannatech sought, and will continue to seek, strategic alliances with several large manufacturers of nutritional supplements. These companies work with Mannatech to create, develop and manufacture its proprietary products. Mannatech also works with other smaller companies to identify and develop new innovative products that complement its existing products.

Associate Support Philosophy. Mannatech is committed to providing the highest level of support services to its associates and believes that it meets the needs of, and builds loyalty with, its associates through its highly personalized and responsive customer service. Mannatech sponsors four to six associate events throughout

the year to provide education and motivation for thousands of associates. These events offer information, aid in business development, provide a venue for launching new products and allow associates the ability to interact with Mannatech's leading distributors and researchers.

Flexible Operating Strategy. Flexibility is a key part of Mannatech's ongoing operations. Mannatech currently outsources production and formed strategic alliances to minimize capital expenditures where practicable. Mannatech uses the expertise and resources of its strategic allies in the areas of distribution and logistics, call center operations, product registration and export requirements. Mannatech also continues to monitor its operating strategy to try to operate in an efficient and cost-effective manner.

Experience and Depth of Mannatech's Management Team. Mannatech made significant management changes based on recent international expansion and lower than expected operating results. Within the last 12 months, Mannatech hired a new Chief Executive Officer, new Chief Information Officer and new President of International Operations. Mannatech also shifted certain management duties to its President and Chief Operating Officer. Finally, Mannatech hired its former President as a Global Vision Architect consultant, to concentrate his efforts and expertise on expansion, motivation and retention of Mannatech's associate base. Mannatech believes these management changes made during 2000 created a management group with a variety of backgrounds and expertise in various fields, including:

- . product research and development;
- . marketing;
- . direct sales and network marketing;
- international operations;
- finance and analysis;
- . legal and compliance;
- information technology; and
- product distribution.

All of Mannatech's principal managers have substantial business experience, primarily with larger businesses. These managers are able to bring the perspective of traditional business to Mannatech's network marketing system. The primary goal of Mannatech is to provide a sound, systematic and reliable framework within which each associate can fit his or her personal style of conducting business.

# **Growth Strategy**

Mannatech's growth strategy is to:

- Introduce New Products. Since its inception, Mannatech has and intends to continue to introduce new products each year. Mannatech expects each new product to contain one or more proprietary components and to complement existing products.
- Attract and Retain New Associates and Enhance Associate Productivity. Mannatech focuses on its operating strengths and strives to create a business climate that recognizes associates for their achievements. Mannatech has introduced several new incentive programs for its associates, including a car bonus and "fast-start" programs. Further, Mannatech plans to simplify its incentive program for its associates, in part to encourage greater retention, motivation and productivity. In addition, Mannatech will continue to modify its associate events and recognition programs to encourage retention and growth in the number of associates. No single associate accounted for more than 10% of total sales, in 2000.

. Expand its Existing International Markets. Mannatech believes the potential for growth also exists in its international markets based upon its experience over the past year. Mannatech currently operates in Canada, Australia, the United Kingdom and Japan. In February 2001, Mannatech hired Mr. C. Armando Contreras to lead its international team of employees. Mr. Contreras brings to Mannatech considerable experience in network marketing as well as international market development. Mannatech suspended its plans to enter the New Zealand market in order to concentrate on growing its existing markets.

### Products and Product Development

Mannatech believes it markets quality and proprietary products that include 26 different nutritional products and 3 topical products. Mannatech also offers a variety of sales aids, including enrollment and renewal packs, brochures, videotapes and a personalized website for its associates. Sales aids accounted for approximately 18.9%, 17.6% and 17.3% of net sales in 1998, 1999 and 2000, respectively.

Mannatech scientists believe that the discovery and use of certain carbohydrates offer significant potential for nutritional benefits. Healthy bodies are comprised of many sophisticated components working together, which must have accurate internal communication to function at an optimal level. In its most basic form, this communication occurs at the cellular level and is referred to by molecular biologists as cell-to-cell communication. To maintain a healthy body, cells must "talk" to other cells. Scientists have learned that certain molecules found on the surface of all cells, called "glycoproteins," play an essential role in all cell-to-cell communication. The name "glycoprotein" is derived from the molecules' composition: sugar, known as "glyco," and protein. The body's need for carbohydrates is important because up to 85% of glycoproteins are composed of specific monosaccharides. Mannatech believes that these carbohydrates are necessary to support and maintain optimal health.

Harper's Biochemistry, a leading biochemistry reference source, lists eight monosaccharides commonly found in human glycoproteins that are important to the healthy functioning of cell-to-cell communication, in the human body. These monosaccharides are as follows:

- fucose;
- . galactose;
- . glucose;
- . mannose;
- N-acetylgalactosamine;
- . N-acetylglucosamine;
- . N-acetylneuraminic acid; and
- . xylose.

From the universe of approximately 200 monosaccharides found in nature, Mannatech's proprietary ingredient, Ambrotose(R) complex, is designed to provide certain of the monosaccharides listed above that are necessary for optimal cell-to-cell communication.

Mannatech focuses on bringing new proprietary and, where possible, patentable, products to market when expanding its existing product line. Research and development costs related to specific clinical studies, quality assurance programs and new product development were approximately \$391,000, \$439,000 and \$392,000 in 1998, 1999 and 2000, respectively. Mannatech also incurred research and development costs related to designing new products, enhancing existing products, Food and Drug Administration compliance studies, general supplies, internal salaries and consulting fees of approximately \$3.4 million in 1998, \$3.6 million in 1999 and \$4.4 million in 2000.

The following chart lists Mannatech's products and the body systems targeted by each, as of December 31, 2000:

	Cell-to-Cell Communication			Intestinal System		Sports Performance	Nutritional Needs
Ambroderm					Х		
AmbrostartTM	X			X		X	
Ambrotose(R)	Χ						
Bulk Ambrotose(R)	Χ						
Bulk EmPactTM						Х	
EmPactTM						Х	
Emprizone(R)					Х		
Firm					Х		
GlycoLEANTM							
Accelerator	X	Χ	X				
GlycoLEANTM Catalyst	X	Χ	X				
GlycoLEANTM Fiber Full	X	Χ	X				
GlycoLEANTM Manager	X	Χ	X				
GlycoSLIMTM Drink	Χ	Χ	X				
ImmunoStartTM							
Chewables	Χ	Χ					
ManAloe(R)	X						
MannaBARTM Carbohydrate							
Formula	X	Χ	X				
MannaBARTM Protein							
Formula	Χ	Χ	Χ				
MannaBARTM Apple-Yogurt							
Crunch	Χ	Χ	Χ				
Manna-CTM		Χ					
MannaCleanseTM				Χ			
Mannatonin			X				
MVPTM			X				
Optimal Health PackTM	Χ	Χ	X				
Bulk PhytAloe(R)		Χ					
PhytAloe(R)		Χ					
PhytoBears(R)		Χ					
Plus			X				
Profile 1							Χ
Profile 2							X
Profile 3							X
Sport with							
Ambrotose(R)						Х	
						•	

Mannatech introduced the following new products in 2000:

- . Optimal Health Pack(TM)-- a convenient pack that contains 60 individually-wrapped packages of Mannatech's most popular supplements: Ambrotose(R) capsule, Phyt-Aloe(R) capsule and Plus caplet; and
- . ImmunoStart(TM) Chewables-- a chewable tablet that energizes and optimizes the immune system, especially in times of stress.

The following chart indicates the year Mannatech introduced its products:

Year Products Introduced

1994 ManAloe(R), Plus, MVP(TM), Ambroderm, PhytAloe(R), Firm

- 1995 PhytoBears(R), EmPact(TM), Emprizone(R)
- 1996 Ambrotose(R), Mannatonin, Profile 1, 2 and 3, Sport with Ambrotose(R)
- 1997 Bulk Ambrotose(R), Bulk EmPact(TM), MannaCleanse(TM)
- 1998 MannaBAR(TM) Carbohydrate Formula, MannaBAR(TM) Protein Formula, Manna-C(TM), Ambrostart(TM), Bulk PhytAloe(R)
- 1999 MannaBAR(TM) Vanilla Apple-Yogurt, GlycoLEAN(TM) Accelerator, GlycoLEAN(TM) Catalyst, GlycoLEAN(TM) Fiber Full, GlycoLEAN(TM) Manager and GlycoSLIM(TM) Drink mix (three flavors--chocolate, vanilla and strawberry)
- 2000 Optimal Health Pack(TM) and ImmunoStart(TM) Chewables

Mannatech plans to release additional products when new nutritional compounds or areas of consumer demand are identified. All new products are expected to contain its proprietary components. Mannatech usually launches new products during its corporate events. New products selected for development are based on:

- . the marketability and proprietary nature of the product;
- . regulatory considerations;
- . the availability of ingredients; and
- . the existence of data supporting claims of functionality.

To ensure quality control and to support, validate and monitor the proprietary nature of its products, Mannatech's quality assurance department conducts appropriate research both before and after product launches and continuously throughout the year by taking samples directly from shipments received from manufacturers.

Product Distribution System

Overview. The foundation of Mannatech's sales philosophy and distribution system is network marketing. Mannatech believes that its network-marketing system is an effective vehicle to distribute its products for the following reasons:

- it is easier to explain the benefits of Mannatech's products in a person-to-person, educational setting;
- . it is more direct and personal than television and print advertisements;
- . direct sales allow potential consumers to actually test the products;
- there is greater impact on the consumer from associate and consumer testimonials;
- it assists in building a base of potential consumers for additional products;
- associates can provide higher levels of customer service and attention by following up on sales to ensure proper product usage and customer satisfaction; and
- . direct contact with customers help to facilitate repeat purchases.

Mannatech encourages, but does not require, associates to use its products, nor does it require a person to be an associate in order to purchase its products. Mannatech believes its network marketing system is particularly attractive to prospective associates for the following reasons:

- . the potential for income;
- . no requirement to purchase inventory;
- . no need to collect money from customers;
- . limited paperwork involved in the sales process; and
- . a flexible work schedule.

Mannatech suggests associates enroll new associates with whom the associates have relationships such as: family members, friends, business associates, neighbors or otherwise. Mannatech believes that associates will be more likely to remain active if they are enrolled by someone with whom they have an ongoing relationship.

Associates pay for products purchased prior to shipment. Mannatech carries no accounts receivable from its associates, except for amounts owed for check returns or other exceptions. Associates generally pay for products by credit card; however, orders are also paid with cash, money orders and checks. Associates may automatically order products on a continuous basis and receive a discount. Automatic orders accounted for approximately 44.9%, 47.1% and 49.2% of net sales for the years ended December 31, 1998, 1999 and 2000, respectively.

Advances in communications, including telecommunications, the Internet and the increasing use of videotape players, fax machines and personal computers have enhanced the effectiveness of network marketing as a distribution channel in the past decade. Mannatech offers high-quality video and audiotapes for use in product education, demonstrations and sponsoring activities. In March 2000, Mannatech substantially completed its science-based website, www.GlycoScience.com, which allows users to search for science-based information about various nutritional ingredients, some of which are found in Mannatech's products. Mannatech believes these sales aids play an important role in the success of its associate efforts and Mannatech is committed to using current and future technological advances to enhance the effectiveness of the network marketing efforts of its associates.

Associate Development. Mannatech believes key contributing factors to its long-term growth and success will be the recruitment of new associates and the retention of existing associates. Mannatech is active in the development of its associates, which includes the areas of recruitment, support, motivation and compensation.

Mannatech primarily relies on existing associates to enroll new associates. The enrollment of new associates creates multiple levels in the network marketing structure. These new associates are referred to as "downline" or "sponsored" associates. Associates can purchase products directly from Mannatech at wholesale prices and can sponsor other associates in order to build a network of associates and product users.

Mannatech also relies heavily on existing associates to train new associates. Mannatech's master associate training course, an advanced training program for associates, was developed using both the expertise of experienced corporate trainers and the experience of seasoned associates. While Mannatech provides brochures, magazines and other sales materials, advanced training is especially designed to provide systematic and uniform training to associates about Mannatech and its products, compensation plan and methods of doing business. Mannatech continues to update its training courses to ensure that its associates receive the latest information on its products, sales aids, technology advances, and sales methods available.

The needs of Mannatech's associates are a priority and Mannatech believes that the high level of support it provides for its associates' efforts is important to Mannatech's success. Mannatech provides a large number of support services tailored to the needs of its associates, including:

- . motivational meetings;
- . educational and informative conference calls;

- . automated fax services;
- . an efficient ordering and distribution system;
- . personalized customer service via telephone, Internet and e-mail;
- 24-hour, seven days per week access to information through touch-tone phones and the Internet;
- . web-based conference calls;
- a current database of each associates' downline information;
- business development materials that Mannatech believes will help increase product sales and recruitment; and
- . an innovative website database, www.GlycoScience.com, designed to provide a user with the ability to search and provide science-based information about nutritional ingredients, some of which are included in Mannatech's products.

Mannatech currently recognizes associate performance with four levels of associate leadership achievement:

- . regional;
- . national;
- . executive; and
- presidential.

The level of associate leadership is based upon the associates' downline growth and commissionable sales. Commissionable sales are sales of products with assigned product point volume. Generally, sales aids are not assigned any product point volume. Each leadership level provides the opportunity for compensation, ranging from 15% of commissionable sales at the regional director level to 9% of commissionable sales at the presidential level, excluding the generational bonus. An associate can achieve four levels within presidential status. The levels are bronze, silver, gold and platinum. In addition, associates are eligible for a "generation bonus," which is an additional achievement level specially designed to motivate sales and downline growth. In 2001, Mannatech intends to simplify its plan, yet expand its associate recognition programs as necessary to reward increased levels of performance and to further motivate its associates.

Associate Compensation. Mannatech's plan combines the aspects of two widely used multilevel marketing compensation plan concepts. Mannatech's plan pays commissions based on a percentage of the associate's commissionable sales and the attainment of certain associate leadership levels. The elements of Mannatech's compensation plan are similar to other multi-level marketing compensation plans. In addition each associate may determine their own optimal resale price of products purchased from Mannatech.

Mannatech's compensation plan attempts to compensate an associate both in the early stages of building their business and when the associate has developed their business, by rewarding the associate for breadth and depth in their downline organizations. Mannatech's compensation plan pays the following:

- . a bonus or commission to qualified associates, ranging from \$20.00 to \$180.00 based on downline growth and commissionable product sales;
- . \$25.00 to an associate for each eligible associate they train if they have completed advanced training and obtained the all star level;
- . bonuses or commissions ranging from \$10.00 to \$200.00 based on products included in starter or renewal packs sold;

- a "fast-start" bonus, ranging from \$100.00 to \$500.00, for a new associate who obtains regional or national level within three months of initially signing up as an associate;
- a "car incentive" bonus, ranging from \$200.00 to \$700.00, for an associate who achieves certain sales levels and who has increased their product sales by at least 10% from their previous year's sales volume; and
- . various other bonus programs including earning various promotional travel awards.

Based upon the knowledge of industry-related network marketing compensation plans, Mannatech believes that its compensation plan is among the most financially rewarding plans offered in the industry. Mannatech's commissions as a percentage of net sales was 40.4%, 40.9% and 41.2% for 1998, 1999 and 2000, respectively.

Mannatech does not employ the entire compensation plan described above outside of the United States and Canada. In the international sector, Mannatech uses similar plans with regard to commissionable product sales that are tailored to fit the laws and considerations governing compensation of associates in each country. Mannatech integrated its international compensation plan across all markets in which its products are, or will be sold, thereby allowing associates to receive commissions for global product sales. Mannatech refers to this as its "global seamless downline structure" and hopes it will help associates to build their global networks by expanding their downlines into international markets without having to establish new downlines or requalify for higher levels of commissions within each new country. Mannatech's international compensation plan is designed to pay approximately the same percentage compensation as in the United States and Canada.

Management of Associates. Mannatech believes it takes an active role in the management of its associates. Mannatech believes any oversight process is complicated because the associates are independent contractors and not employees of Mannatech. Mannatech seeks to restrict the statements and conduct of associates regarding its business by contractually binding associates to abide by its associate policies and procedures. Each associate receives a copy of the policies and procedures that must be followed in order to maintain associate status with Mannatech. Associates are expressly forbidden from making any representation of the possible earnings of any associate, other than through statements by Mannatech indicating the range of actual earnings by all associates. Mannatech also monitors its associate websites for content on a continuing basis and introduced MannapagesTM, a standardized, personal, Internet website program established to assist Mannatech in monitoring associate websites on a regular basis, and help associates in their sales efforts.

Mannatech has established a compliance program for addressing associates who do not comply with its policies and procedures. Mannatech has developed formal steps for proceeding if a complaint is filed against an associate. Mannatech's primary goal is to educate its associates to ensure they understand and follow all of Mannatech's policies and procedures. Mannatech's compliance and legal departments, in cooperation with other departments, regularly evaluate associate conduct and the need for new and revised policies. Mannatech believes its compliance program assists in the maintenance of associate ethics and help associates in their sales efforts.

Product Return Policy. Mannatech's product return policy states that any retail customer may return the unused portion of any product to the selling associate and receive a full cash refund from the associate. Mannatech will then reimburse any associate who provides a refund to a retail customer with product if they provide Mannatech with the proper documentation and return the remainder of the product to Mannatech. Mannatech's product return policy for associates states that any associate will receive a 90% refund of the wholesale cost for any returned, unopened, restockable products and any up-to-date corporate literature that is in good, usable condition. Historically, product returns have not been significant and returns as a percentage of net sales were 1.7%, 1.0% and 0.8% in 1998, 1999 and 2000, respectively.

## Information Technology and Systems

Mannatech believes that maintaining sophisticated and reliable transactions-processing systems is essential to its long-term success. Mannatech's systems are designed to:

- reduce the time required to supply an associate or customer with products;
- . provide detailed and customized ordering information;
- . respond quickly to associate needs and information requests;
- provide detailed and accurate information concerning qualification and downline activity;
- . provide detailed reports of commissions paid to the associate;
- . support the customer service department; and
- . help to monitor, analyze and report financial and operating results.

During 2001, Mannatech expects to spend approximately \$6.6 million on its information technology operations of which approximately \$1.7 million will be for capital expenditures. These expenditures will help to provide new technology to continue to address the needs of associates and expand transaction-processing systems to accommodate international operations. Mannatech believes the significant investment in software, hardware and personnel will enable it to:

- respond rapidly to its business needs for information technology assessment and development;
- . manage international operations and its seamless downline structure;
- . help identify areas in which Mannatech can reduce operating expenses; and
- . safeguard Mannatech's database.

Mannatech's sophisticated financial system includes a report-writing system that is windows-based and capable of operating on several platforms. The financial system enables Mannatech to track and analyze financial information and create and produce customized reports. Mannatech believes its systems are adequate for its immediate future needs.

# Production and Distribution

All of Mannatech's products are manufactured by outside contractors. This strategy provides Mannatech with the virtual production capacity necessary to respond to fluctuations in its sales, but limiting its investment in capital equipment. Mannatech believes that it currently has the contract manufacturers' support necessary to meet inventory requirements over the next several years. Mannatech continues to identify new quality-driven manufacturers to supply the products necessary for its success. Mannatech also continues to seek cost-cutting measures by periodically reviewing current pricing considerations and by requiring competitive bids from various manufacturers that meet its quality and performance requirements.

Mannatech currently acquires its ingredients from superior suppliers of such ingredients and has identified dependable alternative sources for all of its ingredients except Manapol(R) and Arabinogalactan, which are components of Ambrotose(R) complex. With these alternative sources, Mannatech could produce, purchase or replace any of the ingredients if it was unable to purchase any of these ingredients from its current suppliers. In January 2000, Mannatech signed a new supply agreement with its supplier of Manapol(R) and in February 2001, modified the purchasing requirements of the supply agreement. The supply agreement requires Mannatech to buy a minimum monthly volume at an agreed-upon price through August 2002.

Mannatech's distribution operation is located in Coppell, Texas, and consists of 75,000 square feet of leased space in which it maintains its automated system capable of processing up to 18,000 orders per day. This system enhances productivity and will support sales volume growth. The distribution facility contains

warehouse and distribution offices. Mannatech also has contract distribution facilities in Canada, Australia, the United Kingdom and Japan. For further information on these contract facilities see "Properties" on page 18 of this report.

# **Government Regulations**

In the United States, network marketing activities are regulated by a large number of laws, governmental regulations, administrative determinations, court decisions and similar legal requirements at the federal, state and local levels. These regulations address, among other things:

- . network marketing systems;
- transfer pricing and similar regulations affecting the amount of foreign taxes and customs duties paid;
- taxation of associates, and the requirement to collect taxes and maintain appropriate records;
- . how a company makes, packages, labels, distributes, imports, sells and stores products;
- . product ingredients;
- . product claims;
- advertising; and
- . the extent in which a company may be responsible for associates' claims about its products.

Products. The following governmental agencies regulate some aspect of Mannatech's business or its products in the United States:

- . the Food and Drug Administration;
- . the Federal Trade Commission;
- . the Consumer Product Safety Commission;
- . the Department of Agriculture;
- . the Environmental Protection Agency;
- . the Postal Service; and
- . various agencies of the states and localities, in which Mannatech's products are sold.

The Food and Drug Administration regulates the formulation, manufacture, packaging, storage, labeling, promotion, distribution and sale of foods, dietary supplements and over-the-counter drugs. Food and Drug Administration regulations require both Mannatech and its suppliers to meet good manufacturing practice regulations for the preparation, packing and storage of its products and has published a Notice of Advanced Rule Making for good manufacturing practices for dietary supplements. On January 6, 2000, the Food and Drug Administration issued a final rule called "Statements made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body." Mannatech believes this final rule has not had an adverse effect as it was already in compliance.

The Dietary Supplement Health and Education Act of 1994 revised the provisions of the Federal Food, Drug and Cosmetic Act concerning the composition and labeling of dietary supplements. Mannatech believes this act is generally favorable to the dietary supplement industry because it created a new class, by statute, of "dietary supplements," which includes vitamins, minerals, herbs, amino acids and other dietary substances for human use to supplement the diet. This act grandfathers, with certain limitations, dietary ingredients on the market before October 15, 1994. A dietary supplement that contains a dietary ingredient that was not on the market before October 15, 1994 must provide evidence establishing that the supplement is reasonably expected

to be safe. Manufacturers of dietary supplements that make a "statement of nutritional support," thereby describing certain types of product performance characteristics, must:

- . have evidence that the statement is truthful and not misleading;
- . make a disclaimer in the statement itself; and
- . notify the Food and Drug Administration of the statement no later than 30 days after the statement is first made.

The majority of the products that Mannatech markets are classified as dietary supplements under the Federal Food, Drug and Cosmetic Act. In 1999, the Food and Drug Administration issued new regulations governing the labeling and marketing of dietary supplement products. These regulations include:

- the identification of dietary supplements and their nutrition and ingredient labeling;
- the wording used for claims about nutrients, health claims and statements of nutritional support;
- labeling requirements for dietary supplements for which "high potency" and "anti-oxidant" claims are made;
- . notification procedures for statements on dietary supplements; and
- premarket notification procedures for new dietary ingredients in dietary supplements.

Mannatech is required to continue its ongoing program of providing evidence for its product performance claims, and to notify the Food and Drug Administration of certain types of performance claims made for its products. Mannatech's substantiation program involves compiling and reviewing the scientific literature pertinent to the ingredients contained in its products.

In certain markets, including the United States, claims made by Mannatech with respect to dietary supplements, personal care or any of its other products may change the regulatory status of the product. For example, in the United States, the Food and Drug Administration could possibly take the position that claims made for some of Mannatech's products make those products new drugs requiring preliminary approval. The Food and Drug Administration could also place those products within the scope of a Food and Drug Administration overthe-counter drug monograph. Over-the-counter monographs dictate permissible ingredients, appropriate labeling language and require the marketer or supplier of the products to register and file annual drug listing information with the Food and Drug Administration. Emprizone(R) is the only product Mannatech sells that is labeled as an over-the-counter monograph drug. If the Food and Drug Administration asserts that the product claims cause it to be considered new drugs or fall within the scope of over-the-counter monographs, Mannatech would be required to file a new drug application and comply with the applicable monographs or change the claims made in connection with such products.

Dietary supplements are also subject to the Nutrition, Labeling and Education Act, which regulates health claims, ingredient labeling and nutrient content claims characterizing the level of a nutrient in a product. This act prohibits the use of any health claim for dietary supplements unless the health claim is supported by significant scientific research and is pre-approved by the Food and Drug Administration.

The Federal Trade Commission regulates the marketing practices and advertising of all of Mannatech's products. In the past several years, the Federal Trade Commission instituted enforcement actions against several dietary supplement companies for false and misleading marketing practices and advertising of certain products. These enforcement actions have resulted in consent decrees and monetary payments by the companies involved. The Federal Trade Commission has also increased its review of the use of the type of testimonials Mannatech uses in its business. The Federal Trade Commission requires reasonable evidence proving product claims at the time that such claims are first made. The failure to have this evidence when product claims are first made violates the Federal Trade Commission Act. Although the Federal Trade Commission has never

threatened an enforcement action against Mannatech for the advertising of its products, there can be no assurance that the Federal Trade Commission will not question Mannatech's advertising or other operations in the future.

Mannatech cannot predict the contents of any future laws, regulations, interpretations or applications or the future impact of different governmental regulations; however, any or all of such requirements maybe costly to Mannatech. Future regulations could require Mannatech to:

- . change in the way it conducts business;
- . change its product contents;
- . keep additional records;
- . increase the available documentation of its product properties; and/or
- . increase or use different labeling and scientific proof of product ingredients, safety or usefulness.

Network Marketing System. Mannatech's network marketing system, which includes Mannatech's compensation plan, is controlled by a number of federal and state statutes and regulations, and is administered by the Federal Trade Commission, various state authorities and foreign government agencies. The legal requirements controlling network marketing organizations are, in part, directed to ensure that product sales are ultimately made to consumers. In addition, achievement within these organizations must be based on sales of products rather than compensation from the recruitment of additional associates, investments in the organizations or other non-retail sales-related criteria. For instance, various states or provinces limit the amount associates may earn from commissions on sales by other associates, not directly sponsored by the associate. Mannatech believes it has and will continue to obtain regulatory approval of its network marketing system in jurisdictions that require such approval. If regulatory approval is not required, Mannatech relies on the advice of counsel to ensure regulatory compliance.

As a result of contents contained in an associate's self-generated literature, the Michigan Attorney General's office contacted Mannatech in the summer of 1999 and asked Mannatech to provide data maintained under a consent decree. In addition, the Attorney General requested documentation of the measures taken to address the associate's conduct, the measures implemented in order to prevent a violation of the decree from occurring and the measures that would be implemented in the future to help ensure compliance with the consent decree. Mannatech cooperated and believes it complied with this request. In order to comply with the State of Michigan's Franchise Investment law against involuntary inventory stockpiling, Mannatech monitors its associates in the state of Michigan by conducting random audits of its associates in Michigan to identify evidence of stockpiling and coerced sales. To date, Mannatech has found no evidence of coerced sales or stockpiling by its associates in Michigan. Mannatech designed its associates' policies and procedures to provide no incentive or reward to an associate for engaging in such activities.

In Canada, Mannatech's network marketing system is regulated by both national and provincial law. Under Canada's Federal Competition Act, Mannatech must make sure that any representations relating to associate compensation made to prospective associates constitute fair, reasonable and timely disclosure and that it meets other legal requirements of the Federal Competition Act. Mannatech's compensation plan has been reviewed and no objection to its provisions was received from the appropriate Canadian authorities. All Canadian provinces and territories other than Ontario have legislation requiring that Mannatech register or become licensed as a direct seller within that province. Licensing is designed to maintain the standards of the direct selling industry and to protect the consumer. Some provinces require that both Mannatech and its associates be licensed. Mannatech believes it holds all of the required provincial or territorial direct sellers' licenses.

In Australia, Mannatech's network marketing system is subject to both federal and state regulation. The compensation plan in Australia is designed to meet state requirements and the requirements of Australia's Trade Practices Act. Mannatech's business and trade practices and those of its associates, are regulated by state law and the Trade Practices Act. Claims and representations relating to its products are regulated by both the Trade Practices Act and Australia's Therapeutic Goods Act.

In the United Kingdom, Mannatech's network marketing system is subject to national regulations. The compensation plan in the United Kingdom is designed to meet national requirements, the requirements of the Fair Trading Act of 1973 and the Trading Schemes Regulations of 1997. Mannatech's business and trade practices, and those of associates are regulated by the Direct Selling Association Code of Business Conduct and the U.K. Codes of Advertising and Sales Promotion. Claims and representations relating to Mannatech's business are regulated by the Trading Standards Office.

In Japan, Mannatech's network marketing system, business and trade practices, compensation plan and associates are governed by the Door-to-Door Sales law as enacted in 1976 by the Department of Trade and Ministry.

Other Regulations. Mannatech is also subject to a variety of other regulations in various foreign markets, including:

- . social security assessments and taxes;
- . value added taxes;
- . goods and services taxes;
- . sales taxes;
- consumption taxes;
- customs duties;
- . employee/independent contractor regulations;
- . employment and severance pay requirements;
- . import/export regulations; and
- . antitrust laws.

For example, in many markets Mannatech is restricted in the amounts and types of rules and termination criteria that it can contractually impose on its associates. If Mannatech does not comply with these restrictions, it may be required to pay social security or other tax or tax-type assessments on behalf of its associates, and may incur severance obligations to terminate the associate. In some foreign countries, Mannatech may also be subject to such taxes or payment requirements.

In some countries, including the United States, Mannatech is also governed by regulations concerning the activities of its associates. Regulators may find that Mannatech is responsible for its associates' conduct and may request or require that Mannatech take steps to make certain that its associates comply with these regulations. The types of conduct governed by regulations include, in part:

- . claims made about products;
- . promises or claims of income by Mannatech or its associates; and
- sales of products in markets where the products have not been approved, licensed or legally allowed for sale.

In some markets, including the United States, improper product claims by its associates could cause Mannatech's products to be reviewed or re-reviewed by regulatory authorities. This review could result in Mannatech's products being classified or placed into another category with stricter regulations or requiring labeling changes.

Compliance Procedures. To comply with the many regulations that apply to its business, Mannatech has developed formal compliance measures that include associate disciplinary procedures and internal policies for compliance with the Food and Drug Administration and Federal Trade Commission rules and regulations.

Mannatech continues to research laws governing associate conduct and to revise or alter its business system, compensation plans, associate requirements and other materials and programs as required by laws and regulations in each market. Mannatech attempts to educate its associates about acceptable business conduct in each market through policies, procedures, manuals, seminars and other training materials and programs. Mannatech is able to perform only limited monitoring procedures to make certain that associates comply with existing policies, procedures and regulations, Mannatech cannot promise that all of its associates comply with all existing policies, procedures and regulations.

# Competition

The nutritional supplements industry is large and intensely competitive. Mannatech competes directly with companies that manufacture and market nutritional products with similar product lines, including:

- . Solgar Vitamin and Herb Company, Inc.;
- . Nu Skin Enterprises, Inc.;
- . Twinlab Corporation;
- . Usana, Inc.;
- . Natures Sunshine Products, Inc.; and
- . Weider Nutrition International, Inc.

Nutritional supplements are offered for sale in a variety of ways. While Mannatech believes that consumers appreciate the convenience of ordering products from home through a sales person or the Internet, the buying habits of many consumers who purchased products through traditional retail methods are difficult to change. The number of Mannatech's products in each product category is also relatively small compared to the wide variety of products offered by many other nutritional product companies.

Mannatech also competes for new associates with other retail, multilevel marketing and direct selling companies in the nutritional supplements industry. Many of its competitors and other direct selling organizations have longer operating histories, are better known and have greater financial resources. These competitors include:

- . Amway Corporation;
- . Nu Skin Enterprises, Inc.;
- . Body Wise International, Inc.;
- . ENVION International;
- . Herbalife International, Inc.;
- . Mary Kay Cosmetics, Inc.;
- Forever Living Products, Inc.; and
- . Melaleuca, Inc.

Mannatech believes it competes for new associates by stressing the ease of its delivery system, the superiority of its compensation plans and its proprietary and quality products. Because the pool of individuals interested in direct selling is limited in each market, available recruits are reduced when other network marketing companies successfully recruit these people into their businesses.

# **Employees**

As of December 31, 2000, Mannatech employed 263 people in the United States, of which 10 people occupy executive postions. Mannatech also employs 14 people in Australia 12 people in the United Kingdom and 15 people in Japan. This number does not include Mannatech's associates, who are independent contractors and not employees of Mannatech. Mannatech employees are not unionized and Mannatech believes it has a good relationship with its employees.

# Item 2. Properties

Mannatech leases property at several locations for its headquarters and distribution facilities, including:

Location	Square Feet	Term	Expiration Date
Coppell, Texas (corporate headquarters)	110,000	10 years	January 2007
center)(1) Dallas, Texas (Internet subsidiary	75,000	10 years	January 2008
headquarters)(2)st. Leonards, Australia (Australian	6,400	3 years	November 2002
headquarters)Basingstoke, Hampshire (U.K.	9,000	5 years	August 2003
headquarters) Tokyo, Japan (Japanese	1,255	2 years	May 2001
headquarters)	10,000	2.3 years	February and April 2002

- (1) The United States distribution facility is capable of filling 18,000 orders per day and is currently operating at 34% of its full capacity.
- (2) Internet Health Group, Inc.'s headquarters is being subleased for the remaining term of the lease as Mannatech ceased its operations.

Mannatech also has several contract distribution center operations and believes all of its leased facilities are adequate for its operations in the immediate future. Mannatech's contract distribution center operations are as follows:

Location	Feet	per Day Capacity	Current Operating Capacity
Calgary, Alberta	6,000	3,200	20%
Botany, Australia	5,000	20,000	10%
Perth, Australia	1,000	500	2%
Poyle, United Kingdom	5,000	3,200	5%
Tokyo, Japan	7,000	10,000	10%

# Item 3. Legal Proceedings

In October 1997, Mannatech filed a Notice of Objection to the issuance of a registered trademark being issued to IntraCell Nutrition, Inc., which had filed a trademark application for the name, "Manna." On May 19, 2000, Mannatech's Notice of Opposition to the issuance of a registered trademark issued to IntraCell Nutrition, Inc. for the name "Manna" was rejected. To date, no action has been filed against Mannatech by IntraCell, which would contend any infringement by Mannatech on that of IntraCell. If IntraCell brings any infringement action against Mannatech, an adverse determination could have an adverse effect on Mannatech's business, results of operations, financial condition and liquidity.

On August 20, 1999, Mannatech filed a lawsuit against Dr. Daryl See in the United States District Court for the Northern District of Texas alleging, among other things, that he misled Mannatech when he claimed that one of his studies, which Mannatech used to illustrate the positive effects of its products had been funded by the National Institutes of Health and conducted under the auspices of the University of California-Irvine. On May 22, 2000, Mannatech agreed to dismiss all claims against Dr. Daryl See. Under the terms of the settlement agreement, Dr. See's conduct was restricted regarding Mannatech, its products and associates.

On February 24, 2000, Ms. Caroline Rivers filed a class action complaint against Mannatech and three other defendants, in the District Court, County of Boulder, State of Colorado alleging breach of contract, negligence and that the defendants were marketing and selling illegal health insurance policies. On June 29, 2000, Mannatech's Motion for Dismissal was granted and all claims relating to the uncertified class action complaint were dismissed against Mannatech.

On May 30, 2000, Mannatech filed suit for breach of contract in the United States District Court of the Northern District of Texas, Dallas Division, against Gryphon Advisors II, L.L.C., a Delaware limited liability company. Mannatech alleged amounts billed for out-of-pocket expenses and advisory service fees totaling \$1.6 million were unreasonable and that Gryphon Advisors breached the advisory agreement. Under the Advisory agreement, Gryphon was to provide advice on potential financing opportunities, acquisitions, the financial management of Mannatech, all aspects of its capital structure, capital-raising transactions and assist Mannatech in evaluating potential acquisition targets. On June 26, 2000, Gryphon Advisors filed a cross-action suit for breach of contract and fraud seeking the payment of \$1.6 million and exemplary damages. On March 1, 2001, Mannatech and Gryphon Advisors agreed to dismiss its respective claims with prejudice and Mannatech agreed to pay Gryphon Advisors \$650,000 over a 12-month period.

Item 4. Submission of Matters to a Vote of Security Holders

None.

#### PART II

Item 5. Market for Registrant's Common Equity and Related Shareholder Matters

Market for its Common Stock. On February 12, 1999, Mannatech completed its initial public offering and on February 16, 1999, its common stock began trading on the Nasdaq National Market under the symbol "MTEX." As of March 19, 2001 the total number of outstanding shares of its common stock was 24,799,301 and the closing price on such date was \$1.156. Pricing information prior to February 16, 1999 is not available, because Mannatech's common stock was not publicly traded prior to that date. Set forth below are the high and low sales prices of Mannatech's common stock as reported on the Nasdaq National Market for each quarter of the fiscal years ended December 31, 1999 and 2000:

	High	
First Quarter (from February 16, 1999)	\$31.750	\$10.500
Second Quarter 1999	\$23.875	\$10.125
Third Quarter 1999	\$13.625	\$ 6.563
Fourth Quarter 1999	\$ 8.875	\$ 4.625
First Quarter 2000	\$ 5.313	\$ 3.688
Second Quarter 2000	\$ 3.938	\$ 2.125
Third Quarter 2000	\$ 3.875	\$ 1.125
Fourth Quarter 2000	\$ 2.469	\$ 1.234

Holders. As of March 19, 2001, there were approximately 5,011 shareholders of record who hold Mannatech's common stock directly and approximately 133 security brokers and dealers who hold approximately 37.1% of Mannatech's common stock on behalf of approximately 9,000 shareholders.

Dividends. Mannatech shareholders received dividends totaling approximately \$1,326,104 in 1999. Mannatech did not pay any dividends in 2000 and does not intend to pay any dividends in 2001. The Board of Directors intends, from time-to-time, to reevaluate this policy based on its consolidated results of operations, financial condition, cash requirements and other factors deemed relevant. Any future payments of dividends will be subject to the discretion of Mannatech's Board of Directors and subject to certain limitations under the Texas Business Corporation Act.

Sales of Unregistered Securities.

None.

Uses of Proceeds from Registered Securities

None.

## Item 6. Selected Financial Data

The Selected Financial Data set forth below for each of the five years ended December 31, 2000 have been derived from and should be read in conjunction with (A) Mannatech's Consolidated Financial Statements set forth in Item 14, of this report, beginning on page F-1, and (B) "Management's Discussion and Analysis of Financial Condition and Results of Operations," which follows this table.

	Year Ended December 31,						
	1996 1997 1998 1999 2000						
	(in thousands, except per share amounts)						
Consolidated Statement of Income Data:							
Net sales Gross profit Income (loss) from			\$164,933 71,143				
operations	8,240	14,718	16,057	16,081	(8,439)		
accounting change  Cumulative effect of accounting change (1)	7,162	10,622		•			
Net income (loss) Earnings (loss) per common sharebasic:		10,622		10,788			
Before cumulative effect of accounting change Cumulative effect of	\$ 0.35				\$ (0.29)		
accounting change(1)					(0.01)		
Net	\$ 0.35 =====				\$ (0.30) =====		
Earnings (loss) per common sharediluted: Before cumulative effect of							
accounting change Cumulative effect of	\$ 0.35				\$ (0.29)		
accounting change(1)					(0.01)		
Net	\$ 0.35 =====				\$ (0.30) =====		
Weighted average common and common equivalent shares outstanding:							
Basic	20,627 ======		22,102 ======				
Diluted	20,627 ======	22,400	23,659	25,224	24,946		
Pro Forma Information:(2) Income before income taxes, as							
reported  Pro forma provision for income	\$ 8,356	\$ 14,761					
tax expense	3,134	5,683					
Pro forma net income	\$ 5,222 ======	\$ 9,078 ======					
Pro forma earnings per common share:(2)							
Basic	\$ 0.25 ======	\$ 0.42 ======					
Diluted	\$ 0.25 ======	\$ 0.41					
Other Financial Data: Capital expenditures (3) Dividends declared per common	\$ 2,660	\$ 9,135	\$ 6,098	\$ 3,243	\$ 4,109		
share Consolidated Balance Sheet	\$ 10.00(4)	\$ 0.37	\$ 0.39	\$ 0.06	\$		
Data: Total assets Long-term obligations	\$11,410	\$ 19,558	\$ 26,874	\$ 44,779	\$ 38,902		
excluding current portion	\$	\$ 110	\$ 1,056	\$ 325	\$ 527		

 <sup>(1)</sup> Cumulative effect of accounting change is the result of Mannatech adopting Staff Accounting Bulletin No. 101 "Revenue Recognition in Financial Statements" retroactively to January 1, 2000.
 (2) The pro forma information shows net income and earnings per share as if all

<sup>(2)</sup> The pro forma information shows net income and earnings per share as if all income earned by Mannatech and certain related partnerships was taxable at federal and state statutory rates.

- (3) Capital expenditures include assets acquired through capital lease obligations of \$397,402 and \$1,471,986 in 1997 and 1998, respectively.
- (4) Dividends were calculated based upon shares outstanding prior to the stock split and Mannatech's reorganization (10,000 shares), each of which took place in 1997. Aggregate dividends declared amounted to \$100,000 in 1996.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion is intended to assist in the understanding of Mannatech's financial position and results of its operations for the three years ended December 31, 2000. This discussion should be read in conjunction with the Consolidated Financial Statements and related Notes in Item 14, beginning on page F-1. Unless stated otherwise, all financial information presented below, throughout this report and in the Consolidated Financial Statements and related Notes includes Mannatech and all of its subsidiaries on a consolidated basis.

### **Overview**

Mannatech develops and sells proprietary nutritional supplements and topical products in the United States, Canada, Australia, the United Kingdom and Japan, through a worldwide network marketing system of approximately 237,000 active associates as of March 8, 2001, compared to approximately 269,000 active associates as of March 9, 2000.

Mannatech's diluted earnings (loss) per share was (\$0.30) for the year ended December 31, 2000 compared to \$0.43 per share in 1999. This decrease was primarily due to the following:

- . a decrease in sales of \$29.7 million;
- . incurring approximately \$4.1 million in expenses related to its Internet website subsidiary, Internet Health Group, Inc., which includes: funding its operating losses, recording a write-off of its fixed asset software of \$870,000, a write-off of its inventory of \$837,000 and the cancellation of various agreements relating to closing its operations as of December 29, 2000 totaled approximately \$332,000;
- incurring \$4.2 million for start-up expenses relating to the expansion into Japan; and
- accruing \$1.0 million for various severance packages related to the former Chief Operating Officer of International Operations and former Chief Information Officer.

In 2001, Mannatech increased some of the sale prices of its products, starter and renewal packs and shipping fees; however, it believes the negative trend in sales will continue into the first half of 2001. In the future, Mannatech expects its international operations to account for an increasing percentage of consolidated net sales. The net sales by country as a percentage of consolidated net sales were as follows:

Year Ended December 31,	U.S.	Canada	Australia	U.K.	Japan	Total
2000	77.0%	13.5%	5.7%	1.3%	2.5%	100.0%
1999	76.7%	14.3%	8.8%	0.2%	0.0%	100.0%
1998	82.5%	16.1%	1.4%	0.0%	0.0%	100.0%

Net sales for the United States, Canada and Australia continue to decrease as compared to the same period in 1999. Mannatech believes the decrease is due to a number of factors including the following:

- its associates in the United States, Canada and Australia concentrating their efforts on the development of Mannatech's presence in the United Kingdom and Japan;
- . some of its associates exploring new competitive Internet networking companies as another way to supplement their income;
- . associates' concerns about recent management changes; and

. concerns about the decline of Mannatech's stock price which may, in part may have resulted from unanticipated selling pressure.

On October 28, 2000, Mannatech introduced a new product, ImmunoStart(TM) Chewables, which helps trigger immune responses. In March 2001, Mannatech introduced a chewable multi-vitamin for children called Glyco-Bears(TM). Mannatech also intends to introduce other new products during 2001, which it hopes will further complement its current products and help boost net sales.

Mannatech's revenues are primarily derived from sales of its products and associate starter and renewal packs, which include some combination of its products and promotional materials. The purchase of a starter or renewal pack allows the associate to purchase products at wholesale prices. If the associate purchases a pack with a wholesale price of \$300 or higher, the associate also received a \$50 credit toward admission to one of Mannatech's corporate events. In January 2001, Mannatech made changes to some of its packs including a change in product mix, price changes and the discontinuation of the credit toward admission. Mannatech tries to offer a comparable associate starter pack in each country in which it does business; however, each country has different regulatory guidelines that must be followed and therefore not all of Mannatech's packs are offered in all countries.

Mannatech adopted Staff Accounting Bulletin No. 101 "Revenue Recognition in Financial Statements" ("SAB 101") in the fourth quarter of 2000. Under SAB 101, Mannatech is required to defer the recognition of revenues until the associate receives the products shipped. The adoption of SAB 101 resulted in a cumulative effect of accounting change of approximately \$210,000, net of tax of \$126,000.

On average, the wholesale value of the nutritional and topical products contained in each of Mannatech's starter and renewal packs is between 60% and 70% of the total wholesale value of the packs and the remainder of the total wholesale value consists of various promotional materials and products. If the pack contains a credit toward admission to a corporate event, the revenue from the promotional pack is allocated between product revenue and the corporate event admission based on the proportionate fair value of these items. Mannatech defers revenue received from the sale of its promotional packs to the extent that the sales price is greater than the wholesale value of the individual items included in such packs. Allocated corporate event admission revenues are also deferred. All deferred revenue is amortized over a twelve-month period. Total deferred revenue was approximately \$845,000 at December 31, 1999 and \$691,000 at December 31, 2000.

Mannatech compensates its 7 associates by commissions and incentives, which is its most significant expense; however, the commission structure is designed not to materially exceed 42% of commissionable net sales. Mannatech plans to announce some changes to its worldwide compensation plans, yet offer more bonuses and incentive programs and revamp the training program for its associates. The changes would simplify the compensation plan but would not change the total commission paid as a percentage of net sales. Commissions and incentives are paid to associates based on the following:

- . associates' placement and position within the compensation plan;
- . volume of their direct commissionable sales;

- . number of new enrolled associates; and
- . achievement of certain levels to qualify for incentive programs.

In 2000, Mannatech's United States federal statutory tax rate was 34%. Mannatech pays taxes in Australia at a statutory tax rate of approximately 36% and in the United Kingdom at a statutory tax rate of approximately 31%. Mannatech expects to pay taxes in Japan at a statutory tax rate ranging between 42% and 48%. Mannatech also pays taxes in various state jurisdictions at an approximate average effective tax rate of 3%. Due to its international operations, a portion of Mannatech's income will be subject to taxation in the countries in which it operates; however, it may receive foreign tax credits that would reduce the amount of United States taxes owed. Mannatech may not be able to use all of such foreign tax credits in the United States. Mannatech may also incur net operating losses that may not be fully realizable.

## Results of Operations

The following table summarizes Mannatech's consolidated operating results as a percentage of net sales for each of the years indicated:  $\[ \]$ 

	Year Ended December 31,		
	1998	1999	2000
Net sales	16.5 40.4	16.2 40.9	18.0 41.2
Gross profit Operating expenses:		42.9	
Selling and administrative expenses Other operating costs			0.6 
Income (loss) from operations	9.7 (0.1)  0.3	9.0 (0.4) 0.1	(5.6) (0.5) 0.1 0.4
Income (loss) before income taxes and cumulative effect of accounting change	9.5 3.4	9.2	(5.6) (0.8)
Income (loss) before cumulative effect of accounting change		6.0	(4.8) (0.1)
Net income (loss)	6.1%		(4.9)%
Number of starter packs sold	117,003 58,476	140,521 66,119	107,763 63,930
Total number of packs sold		206,640	171,693
Total associates canceling associate status	6,142 ======	5,972	•

Year ended December 31, 2000 compared with the year ended December 31, 1999

Net Sales. Net sales decreased (16.5%) to \$150.0 million in 2000 from \$179.7 million in 1999. This decrease was primarily composed of the following:

 a \$5.0 million increase from the sale of new products introduced during 2000, including the Optimal Health Pack(TM) and ImmunoStart(TM) Chewables;

- . a (\$29.8) million decrease in existing product sales resulting from a decrease in the volume of products sold, and
- . a decrease of (\$4.9) million from associate pack sales. Of this (\$4.9) million decrease, approximately (\$4.2) million resulted from an overall decrease in the number of associate packs sold to new associates. The additional decrease of approximately (\$700,000) resulted from a decrease in the number of associate renewal packs sold. Mannatech is exploring ways and strategies to increase associate pack and renewal pack sales.

Cost of Sales. Cost of sales decreased (6.9%) to \$27.1 million in 2000 from \$29.1 million in 1999. As a percentage of net sales, cost of sales increased to 18.0% in 2000 from 16.2% in 1999. The increase in cost of sales as a percentage of net sales was primarily due to the inventory write-off of Internet Health Group, Inc. and a change in the product mix of finished goods sold. The dollar decrease was primarily due to:

- . the write-off of approximately \$837,000 for the inventory of Internet Health Group, Inc.;
- . a write-off of approximately \$300,000 for obsolete sales aids; and
- . a decrease in volume of finished goods sold.

Commissions. Commissions consist of payments to associates for sales activity and downline growth. Commissions decreased (16.2%) to \$61.7 million in 2000 from \$73.6 million in 1999. As a percentage of net sales, commissions increased to 41.2% in 2000 from 40.9% in 1999. The increase as a percentage of sales was the result of the introduction of new incentive programs during 2000. The dollar decrease was the direct result of a decrease in the number of associate packs sold, which was partially offset by the introduction of new incentive programs for associates, which includes the car bonus and "fast-start" programs.

Gross Profit. Gross profit decreased (20.5%) to \$61.2 million in 2000 from \$77.0 million in 1999. As a percentage of net sales, gross profit decreased to 40.8% in 2000 from 42.9% in 1999. These changes were primarily attributable to the factors described above.

Selling and Administrative Expenses. Selling and administrative expenses include wages, bonuses, shipping and freight and marketing expenses and are a mixture of both fixed and variable expenses. Selling and administrative expenses increased 6.0% to \$37.0 million in 2000 from \$34.9 million in 1999. As a percentage of net sales, selling and administrative expenses increased to 24.7% in 2000 from 19.4% in 1999 due to a decrease in net sales, which did not reduce the fixed and semi-variable expenses. The dollar increase was due primarily to the following:

- a \$1.4 million increase in wages and contract labor, primarily from various pay raises, an increase in personnel for the United Kingdom and Japan and hiring a new Chief Executive Officer and a new Chief Information Officer;
- a \$1.0 million charge for severance packages related to the former Chief Information Officer and former Chief Operating Officer of International Operations;
- a decrease in freight cost of (\$1.0) million;
- . a \$1.7 million increase in expenses related to hosting various events related to international expansion; and
- . a decrease in management bonuses of (\$1.0) million.

Other Operating Costs. Other operating costs include utilities, depreciation, travel, office supplies and printing expenses. Other operating costs increased 21.5% to \$31.7 million in 2000 from \$26.1 million in 1999. As a percentage of net sales, other operating costs increased to 21.1% in 2000 from 14.5% in 1999. The dollar increase was primarily due to the following:

 a \$4.6 million increase for travel, accounting, building rent and consulting services related to the international expansion;

- . recording \$600,000 for the settlement of the Gryphon Advisors L.L.C. lawsuit; and
- . paying Mr. Samuel L. Caster, the former President, \$350,000 for consulting services, as described in the Notes to the Consolidated Financial Statements, in Item 14, of this report, beginning on page F-1.

Write-off of Fixed Asset. In the second quarter of 2000, Mannatech recorded an impairment charge of \$870,000 as it determined the fixed asset software of Internet Health Group. Inc., provided no future benefit. On December 29, 2000, Internet Health Group, Inc. ceased operations.

Interest Income. Interest income decreased (4.1%) to \$684,000 in 2000 from \$713,000 in 1999. As a percentage of net sales, interest income increased to 0.5% in 2000 from 0.4% in 1999. The dollar decrease was primarily due to using investments to fund Mannatech's current year operations, including its international expansion.

Interest Expense. Interest expense decreased (54.0%) to \$69,000 in 2000 from \$150,000 in 1999. As a percentage of net sales, interest expense remained the same at 0.1% in 2000 and in 1999. The dollar decrease was primarily due to the repayment of the existing loan and leases during the year.

Other Expense, Net. Other expense may consist of penalties related to tax payments for payroll, income and sales, foreign currency translation adjustments and miscellaneous non-operating items. Other expense increased 389.5% to \$558,000 in 2000 from \$114,000 in 1999. As a percentage of net sales, other expense increased to 0.4% in 2000 from 0.1% in 1999. For the year ended becember 31, 2000, other expense consisted primarily of translation exchange losses of \$359,000 and \$36,000 in sales tax payments and tax penalties. In 1999, other expense consisted primarily of federal tax penalties.

Income Tax Expense (Benefit). Income tax expense (benefit) decreased to (\$1.2) million in 2000 from \$5.7 million in 1999. Mannatech's effective tax rate decreased to 14.8% in 2000 from 34.7% in 1999. Mannatech's effective tax rate decreased primarily as a result of the establishment of a valuation allowance for the net operating losses from its Japan subsidiary.

Cumulative Effect of Accounting Change. In the fourth quarter of 2000, Mannatech adopted Staff Accounting Bulletin No. 101 "Revenue Recognition in Financial Statements" ("SAB 101") which resulted in a charge of \$210,000, net of tax of \$126,000 for the cumulative effect of the accounting change. SAB 101 requires Mannatech to defer the recognition of revenues until the associates receive products shipped by Mannatech.

Net Income (loss). Net income (loss) decreased to (\$7.3) million in 2000 from \$10.8 million in 1999. As a percentage of net sales, net income decreased to (4.9%) in 2000 from 6.0% in 1999. The decrease was due to net sales decreasing by 16.5%, expenses incurred related to its international expansion, recording various severance packages and discontinuing operations of Internet Health Group, Inc.

Year ended December 31, 1999 compared with the year ended December 31, 1998

Net Sales. Net sales increased 9.0% to \$179.7 million in 1999 from \$164.9 million in 1998. This increase was primarily composed of the following:

- a \$7.8 million increase from the sale of several new products introduced during 1999;
- . a \$4.5 million increase in existing product sales resulting from an increase in the volume of products sold and having operations in Australia open for the entire fiscal year 1999; and
- . an increase of \$2.6 million from associate pack sales. Of this \$2.6 million increase, approximately \$1.5 million resulted from an increase in the number of associate packs sold to new associates. The additional increase of \$1.1 million resulted from an increase in associate renewal packs sold. The increase in the number of packs sold is a result of the international expansion and hiring a marketing firm to concentrate on the associate renewal program.

Cost of Sales. Cost of sales increased 7.3% to \$29.1 million in 1999 from \$27.1 million in 1998. As a percentage of net sales, cost of sales decreased to 16.2% for 1999 from 16.5% in 1998. The decrease in cost of sales as a percentage of net sales was primarily due to changes in the product mix of finished goods sold. The dollar increase was primarily due to:

- . an increase in volume of finished goods sold;
- . the recording of \$160,000 for recovery of inventory in 1998 which had been written off in 1997; and
- . a write-off of approximately \$600,000 for other product changes.

Commissions. Commissions consist of payments to associates for sales activity and downline growth. Commissions increased 10.4% to \$73.6 million in 1999 from \$66.7 million in 1998. As a percentage of net sales, commissions increased to 40.9% in 1999 from 40.4% in 1998. The increase was the direct result of the following:

- . an increase in the number of associate packs sold;
- the introduction of new incentive programs for associates, including the fast-start program;
- . the start of operations in Australia in October 1998; and
- . the start of operations in the United Kingdom in November 1999.

Gross Profit. Gross profit increased 8.3% to \$77.0 million in 1999 from \$71.1 million in 1998. As a percentage of net sales, gross profit decreased to 42.9% in 1999 from 43.1% in 1998. These changes were primarily attributable to the factors described above.

Selling and Administrative Expenses. Selling and administrative expenses include wages, bonuses, shipping and freight and marketing expenses, and are a mixture of both fixed and variable expenses. Selling and administrative expenses increased 9.4% to \$34.9 million in 1999 from \$31.9 million in 1998. As a percentage of net sales, selling and administrative expenses increased to 19.4% in 1999 from 19.3% in 1998. The dollar increase was due primarily to sales increases, which increased freight costs by \$900,000, and a \$2.3 million increase in wages and contract labor expenses resulting from pay raises and an increase in personnel for the Australian and United Kingdom operations.

Other Operating Costs. Other operating costs include utilities, depreciation, travel, office supplies and printing expenses. Other operating costs increased 16.7% to \$26.1 million in 1999 from \$22.4 million in 1998. As a percentage of net sales, other operating costs increased to 14.5% in 1999 from 13.6% in 1998. The dollar increase was primarily due to the following:

- a \$750,000 charge for the cancellation of the remaining incentive contract with Mr. Ray Robbins, as described in the Notes to the Consolidated Financial Statements; in Item 14,of this report, beginning on page F-1;
- \$1.7 million for consulting services related to the international expansion;
- . \$350,000 for settlement of various lawsuits;
- . \$225,000 incurred related to the secondary offering for certain existing shareholders; and
- . \$200,000 for additional research and development costs related to opening Mannatech's laboratory facility.

Write-off of Deferred Offering Costs. During August 1998, Mannatech withdrew its original underwritten institutional/retail offering and recorded a one-time charge of approximately \$847,000.

Interest Income. Interest income increased 675.0% to \$713,000 in 1999 from \$92,000 in 1998. As a percentage of net sales, interest income increased to 0.4% in 1999 from 0.1% in 1998. The increase was primarily due to the receipt of the initial public offering net proceeds, which was invested in interest bearing accounts and certain investments.

Interest Expense. Interest expense increased 183.0% to \$150,000 in 1999 from \$53,000 in 1998. As a percentage of net sales, interest expense increased to 0.1% in 1999 from 0.0% in 1998. The increase was due primarily to the signing of two lease agreements with a bank to purchase various equipment for the warehouse and laboratory facility.

Other Expense, Net. Other expense consists of penalties related to tax payments for payroll, income and sales and miscellaneous non-operating items. Other expense decreased (61.9%) to \$114,000 in 1999 from \$299,000 in 1998. As a percentage of net sales, other expense decreased to 0.1% in 1999 from 0.3% in 1998. In 1999, other expense consisted primarily of federal tax penalties. In 1998, other expense consisted primarily of the write-off of abandoned fixed assets of \$250,000.

Income Tax Expense. Income tax expense remained at \$5.7 million for both 1999 and 1998; however, Mannatech's effective tax rate decreased to 34.7% in 1999 from 36.4% in 1998. The effective tax rate decreased primarily as a result of the establishment of a Foreign Sales Corporation and an overall increase in international sales, which are not subject to state income taxes which averaged 3%.

Net Income. Net income increased 7.3% to \$10.8 million in 1999 from \$10.1 million in 1998. As a percentage of net sales, net income decreased to 6.0% in 1999 from 6.1% in 1998. The dollar amount of the increase was due to net sales increasing by 9%, which was partially offset by expenses incurred related to the international expansion and cancellation of the remaining incentive compensation contract for \$750,000.

Seasonality and Selected Quarterly Statements of Operations

Mannatech believes the impact of seasonality on its results of operations is minimal. Mannatech has and may continue to experience variations on its quarterly results of operations in response to, among other things:

- . the timing of the introduction of new products;
- . the recruiting and retention of associates;
- . the general overall economic outlook;
- . the general industry and network marketing industry conditions; and
- . the consumer perception of its products and overall operations.

As a result of these and other factors, the quarterly results may vary significantly in the future. Period-to-period comparisons should not be relied upon as an indication of future performance since Mannatech can give no assurances that the revenue growth rate in new markets will follow its historical pattern. The market price of Mannatech's common stock may also be adversely affected by the above factors.

The following table sets forth the unaudited consolidated quarterly statement of income data for the periods indicated. In Mannatech's opinion, this information has been prepared on the same basis as its audited Consolidated Financial Statements set forth in this report and includes all necessary adjustments, consisting only of normal recurring adjustments, that are considered necessary to present fairly this information in accordance with generally accepted accounting principles. You should read this information in conjunction with the Consolidated Financial Statements and related Notes in Item 14 of this report, beginning on page F-1. Mannatech's consolidated operating results for any one quarter are not necessarily indicative of results for any future period.

			June 30, 1999(1)								
	(in	millions,	except	per	share	and	pack	informa	tion	)	
Net sales	\$	42.6 18.4	\$		45.0 19.2	\$		45.8 19.8	\$		46.3 19.6
taxes Income tax expense Net income Earnings per share (8)		4.6 (1.7) 2.9			3.4 (1.2) 2.2			5.0 (1.8) 3.2			3.5 (1.0) 2.5
Basic		0.13			0.09			0.13			
Diluted		0.12	-		0.08	\$		0.12			0.10
Number of starter packs sold		32,530		3	3,279			31,299		4	13,413
sold		14,604		1	3,189	_		20,689		1	7,637
Total number of packs sold		47,134 ======			6,468 =====			51,988 ======			,
Total associates canceling associates' status		1,448 ======			1,336 =====			1,608 =====			1,580 =====

	As reported Mar. 31, 2000	As Restated(7) Mar. 31, 2000	As reported June 30, 2000(4)	,	э́о,	` ,	Dec 31, 2000(6)
		(in million	s, except	per share and	pack info	rmation)	
Net sales	\$ 40.3 16.5	\$ 39.7 16.3	\$ 39.3 16.9	\$ 39.0 16.7	\$ 36.2 14.8	\$ 37.4 15.3	\$ 33.9 12.9
and cumulative effect Income tax benefit Cumulative effect of	(0.8) 0.3	(1.0) 0.4	(0.8) 0.2	(0.9) 0.2	(2.1) 0.6	(1.6) 0.4	(4.9) 0.2
accounting change (7) Net loss Earnings per share (8)	() \$ (0.5)	(0.2) \$ (0.8)	\$ (0.6)	\$ (0.7)	\$ (1.5)	\$ (1.2)	\$ (4.6)
Basic	\$ (0.02) ======	\$ (0.03) =====	\$ (0.02) ======	\$ (0.03) =====	\$ (0.06) ======	\$ (0.05) =====	\$ (0.19) ======
Diluted	\$ (0.02) =====	\$ (0.03) =====	\$ (0.02) =====	\$ (0.03) =====	\$ (0.06) =====	\$ (0.05) =====	\$ (0.19) ======
Number of starter packs sold	32,438	32,438	31,135	31,135	24,493	24,493	19,697
sold	18,337	18,337	14,227	14,227	16,215	16,215	15,151
Total number of packs sold	50,775 =====	50,775 =====	45,362 =====	45,362 =====	40,708 =====	40,708 =====	34,848 ======
Total associates canceling associates'							
status	2,496 =====	2,496 =====	1,225 ======	1,225 =====	1,182 ======	1,182 =====	1,049 =====

As

<sup>(1)</sup> For the second quarter of 1999, income before income taxes was reduced by a \$750,000 charge for the cancellation of an incentive contract, \$400,000 for consulting services related to international expansion, \$200,000 for settlement of a lawsuit and \$100,000 for additional research and development costs related to the opening of the laboratory facility.

<sup>(2)</sup> For the third quarter of 1999, income before income taxes has been

reduced by \$225,000 related to the secondary offering of registering shares of Mannatech's common stock for sale by certain shareholders.

- (3) For the fourth quarter of 1999, income before income taxes has been reduced by \$1.0 million related to the start-up expenses for operations in the United Kingdom and Japan.
- (4) For the second quarter of 2000, income before taxes was reduced by \$1.2 million for the start-up of Japan operations, \$870,000 for the write-off of software related to Internet Health Group, Inc. and \$1.0 million related to its ongoing operations.
- (5) For the third quarter of 2000, income before income taxes was reduced by \$800,000 million related to operating Internet Health Group, Inc. and \$1.3 million related to the opening of Japan.
- (6) For the fourth quarter of 2000, income before taxes was reduced by \$1.0 million for severance expenses related to the former Chief Operating Officer of International Operations and former Chief Information Officer and \$1.1 million related to the ceasing operations of Internet Health Group, Inc.
- (7) All of the 2000 quarters have been adjusted for the adoption of Staff Accounting Bulleting No. 101 "Revenue Recognition in Financial Statements," in the fourth quarter of 2000.
- (8) Computed on the basis described in Note 1 in the Notes to the Consolidated Financial Statements.

### Liquidity and Capital Resources

In February 1999, Mannatech received approximately \$9.2 million in net proceeds from the sale of its common stock in its initial public offering. In the initial public offering, certain existing shareholders sold 1,556,016 shares and Mannatech sold 1,500,000 shares of its common stock, at \$8.00 per share. Mannatech used approximately \$6.3 million of the proceeds from the initial public offering for international expansion, including product registration, initial inventory requirements and similar items. The remaining \$2.9 million was used to fund working capital and for general corporate purposes. During 1999, Mannatech also received \$641,271 from the exercise of 475,015 outstanding warrants at \$1.35 per share and received \$785,600 from the exercise of 563,774 stock options at a prices per share ranging from \$1.35 to \$2.00. During 2000, Mannatech received \$363,000 from the exercise of 260,700 stock options at prices per share ranging from \$1.35 to \$2.00.

Mannatech's primary capital requirement is to fund working capital that historically been financed through operations. As a result of expenditures on its facilities, equipment and personnel to support its international expansion, Mannatech's working capital decreased from \$11.7 million at December 31, 1999 to \$7.3 million at December 31, 2000. In 1999, Mannatech invested approximately \$600,000 in the expansion into the United Kingdom. Mannatech paid approximately \$1.3 million in dividends to its shareholders in 1999. In 2000, Mannatech invested approximately \$4.4 million in its expansion into Japan and \$4.1 million to fund operations for Internet Health Group, Inc. Mannatech plans to fund its 2001 working capital through its operations.

In March and August 1998, Mannatech entered into two capital leases with principal amounts of \$631,000 and \$841,000, respectively. These capital leases bear interest at 9.3%, are collateralized by leased assets, are payable in 36 monthly installments and contain various financial covenants. At December 31, 2000, Mannatech violated the annual cash flow coverage ratio covenant but obtained a waiver from the bank on March 14, 2001 that waived this violation at December 31, 2000. In July 1998, Mannatech entered into a 36-month, unsecured note payable with a finance company to finance a 3-year product liability insurance premium. The initial principal amount of this note was \$435,670, with interest at 8.0% and due in monthly installments through December 2000.

Net cash provided by (used in) operating activities was \$18.1 million, \$4.8 million and (\$4.6) million in 1998, 1999 and 2000, respectively. In 1998, operating activities included net income and increases in accrued operating expenses and inventory. In 1999, operating activities consisted of net income, an increase in inventory, a decrease in accured operating expenses and recording the tax benefit related to the exercise of warrants and options. In 2000, operating activities included a net loss and increases in income tax receivable and accrued operating expenses. The increase in accrued operating expenses was the result of recording severance packages and closing operations of Internet Health Group, Inc.

Net cash (used in) investing activities was (\$4.4) million, (\$4.6) million and (\$1.7) million in 1998, 1999 and 2000, respectively. In 1998, these activities consisted of the relocation of the Texas distribution center, the

build-out of the research and development facility and the development and implementation of its proprietary software. In 1999, these activities consisted primarily of purchases of computer hardware, continued internal development of Mannatech's propriety software, furnishings for the Australian and United Kingdom operations and interest from investments of the net proceeds from its initial public offering, which were partially offset by the repayment of notes receivable due from certain shareholders of approximately \$944,000. In 2000, these activities consisted of approximately \$4.1 million for purchases of fixed assets primarily for the Japan operations, offset by the maturities of investments of \$2.3 million and the repayment of the notes receivable due from certain shareholders of approximately \$124,000. Mannatech believes its facilities and software programs should be sufficient for its immediate needs.

Net cash provided by (used in) financing activities totaled (\$12.9) million, \$10.6 million and \$0.6 million in 1998, 1999 and 2000, respectively. In 1998, Mannatech paid dividends on a monthly basis to its shareholders in the amount of \$0.02-\$0.06 per share and paid dividends each month until the completion of the initial public offering on February 12, 1999. During 1999, gross initial public offering proceeds of approximately \$12.0 million were received and proceeds of \$786,000 were received from the exercise of certain stock options, which were partially offset by the repayment of capital leases and a note payable of approximately \$900,000. During 2000, proceeds of approximately \$363,000 were received from the exercise of stock options, which was partially offset by the repayment of capital leases and a note payable of \$730,000, issuance of a \$500,000 loan and lock-up agreement to Mr. Charles E. Fioretti and recording cash overdrafts of approximately \$1.5 million. Under the terms of the lock-up and repurchase agreement, Mannatech will be required for the next 12 months, beginning March 3, 2001 to purchase \$83,333.33 worth of common stock from Mr. Charles Fioretti valued at 90% of the fair market price, in exchange, Mr. Charles Fioretti will be prohibited from trading his shares of Mannatech common stock through March 2, 2002, unless approved by the Board of Directors.

Mannatech believes that its existing capital resources, including gross cash provided by operating activities, bank borrowings and suspension of dividend payments to shareholders, should be adequate to fund its operations for at least the next 12 months. Mannatech has no present commitments or agreements with respect to any acquisitions or purchases of manufacturing facilities or new technologies. Future changes could occur that would consume available capital resources faster than anticipated. Mannatech's capital requirements depend on numerous factors, including:

- . the introduction of new products;
- . changes in the number of associates and the retention rate of the associate base; and
- . research and development efforts.

If existing capital resources are insufficient to meet Mannatech's capital requirements for 2001, Mannatech would be required to raise additional funds, which it cannot assure will be available on favorable terms, if at all.

# Impact of Inflation

Mannatech believes that inflation historically has not had a material impact on its operations or profitability. Mannatech expanded into Australia in 1998, into the United Kingdom in 1999 and into Japan in 2000. Revenues and expenses in foreign markets are currently translated using historical and weighted-average currency exchange rates; therefore a weakening United States dollar would have a positive impact whereas a strengthening United States dollar would have a negative impact on translations of its foreign operations.

Recent Financial Accounting Standards Board Statements

In June 1998, the Financial Accounting Standards Board issued Financial Accounting Standard No. 133, "Accounting for Derivative, Instruments and Hedging Activities" ("FAS 133"). This statement establishes accounting and reporting standards for hedging activites and derivative financial instruments, including certain derivative financial instruments embedded in other contracts. In June 1999, the Financial Accounting Standards Board issued Financial Accounting Standard No. 137, which defers the effective date of FAS No. 133 to fiscal years beginning after June 15, 2000. In June 2000, the Financial Accounting Standards Board issued Financial Accounting Standard No. 138, "Accounting for Certain Derivative Instruments and Certain Hedging Activities," which addressed certain issues causing implementation difficulties. Mannatech has adopted FAS 133 and the corresponding amendments on January 1, 2001. The adoption of this statement is not expected to have a material impact on Mannatech's consolidated financial position, results of operation or cash flows.

## Item 7A. Quantitative and Qualitative Disclosures about Market Risk

Mannatech does not engage in trading market-risk-sensitive instruments and does not purchase as investments, as hedges, or for purposes "other than trading," instruments that are likely to expose it to certain types of market risk, including interest rate, commodity price or equity price risk. Mannatech does have investments but there has been no material change in its exposure to interest rate risk on its investments. Mannatech has not issued any debt instruments, entered into any forward or futures contracts, purchased any options or entered into any swaps.

Mannatech is exposed to certain other market risks, including changes in currency exchange rates as measured against the United States dollar. The value of the United States dollar may affect Mannatech's financial results. Changes in exchange rates may positively or negatively affect its financial results, as expressed in United States dollars. When the United States dollar increases against currencies in which products are sold or a weakening exchange rate against currencies in which Mannatech incurs costs, net sales or costs may be adversely affected. Mannatech has established policies, procedures and internal processes governing the management of its market risk and the use of any financial instruments to manage its exposure to such risks. The sensitivity of earnings and cash flows to variability in currency exchange rate is assessed by applying an appropriate range of potential rate fluctuations to Mannatech's assets, obligations and projected transactions denominated in foreign currency. Based upon its overall currency rate exposure at December 31, 2000, Mannatech does not believe that its exposure to exchange rate fluctuations will have a material impact on the consolidated financial position, results of operations or cash flows. The foreign currencies in which Mannatech has exposure to foreign currency exchange rate risk include Australia, the United Kingdom and Japan. The high and low exchange rates to the United States dollar, for each of these countries, for the year ended December 31, 2000 were as follows:

Country/Currency	High	Low
Australia/Dollar United Kingdom/British Pound		
Japan/Yen	\$0.00987	\$0.00870

Given the uncertainty of the exchange rate fluctuation against the United States dollar, Mannatech cannot determine the dollar effect, if any, of the fluctuation on future business, product pricing, results of operations or financial condition. All statements other than historical information incorporated in this Item 7A are forward-looking statements. The actual impact of future market changes may differ materially due to, among other things, factors discussed in this report.

# Item 8. Financial Statements and Supplementary Data

The Financial Statements and Supplementary Data of Mannatech required by this Item 8 are set forth on the pages indicated in Item 14, of this report, beginning on page F-1.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

## PART III

The information required by Items 10, 11, 12 and 13 of Part III is incorporated by reference to Mannatech's definitive proxy statement to be filed with the Securities and Exchange Commission no later than April 30, 2001.

#### PART IV

Item 14. Exhibits, Financial Statement Schedules and Reports on Form 8-K

### (a) 1. Financial Statements

The following financial statements and the Report of Independent Accountants are filed as a part of this report on the pages indicated:  $\frac{1}{2} \left( \frac{1}{2} \right) = \frac{1}{2} \left( \frac{1}{2} \right) \left( \frac{1}{2} \right)$ 

Index to Consolidated Financial Statements	F-1
Report of Independent Accountants	F-2
Consolidated Balance Sheets as of December 31, 1999 and 2000	F-3
Consolidated Statements of Operations for the Years ended December 31,	
1998, 1999 and 2000	F-4
Consolidated Statements of Changes in Shareholders' Equity for the	
Years ended December 31, 1998, 1999 and 2000	F-5
Consolidated Statements of Cash Flows for the Years ended December 31,	
1998, 1999 and 2000	F-6
Notes to Consolidated Financial Statements	F-7

# (a) 2.Financial Statement Schedules

Financial statement schedules have been omitted because they are either not applicable or the information required therein is included elsewhere in the Consolidated Financial Statements or Notes thereto.

- (a) 3.Exhibits required by Item 601 of Regulation S-K
- 3.1 Amended and Restated Articles of Incorporation of Mannatech dated May 19, 1998, incorporated herein by reference to Exhibit 3.1 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on October 28, 1998.
- 3.2 Amended and Restated Bylaws of Mannatech dated April 27, 1999, incorporated herein by reference to Exhibit 4.3 to Mannatech's Form S-1 (File No. 333-77227) filed with the Commission on April 28, 1999.
- 3.3 First Amendment to the Bylaws of Mannatech dated October 20,1999, incorporated herein by reference to Exhibit 3.4 to Mannatech's Form 10-Q (File No. 000-24657) filed with the Commission on August 14, 2000.
- 3.4 Second Amendment to the Bylaws of Mannatech dated February 22, 2000, incorporated herein by reference to Exhibit 3.4 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on April 2, 2001.
- 3.5 Third Amendment to the Bylaws of Mannatech dated March 6, 2000, incorporated herein by reference to Exhibit 3.5 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on April 2, 2001.
- 3.6 Fourth Amendment to the Bylaws of Mannatech dated November 17, 2000, incorporated herein by reference to Exhibit 3.6 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on April 2, 2001.

- 4.1 Specimen Certificate representing Mannatech's common stock, par value \$0.0001 per share, incorporated herein by reference to Exhibit 4.1 to Mannatech's Amendment No. 1 to Form S-1 (File No. 333-63133) filed with the Commission on October 28, 1998.
- 10.1 1997 Stock Option Plan dated May 20, 1997, incorporated herein by reference to Exhibit 10.1 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.2 1998 Incentive Stock Option Plan dated April 8, 1998, incorporated herein by reference to Exhibit 10.2 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.3 2000 Option Plan dated June 19, 2000, incorporated by reference to Exhibit 10.26 to Mannatech's Form 10-Q (File No. 000-24657) filed with the Commission on November 14, 2000.
- 10.4 Exchange Agreement by and among Mr. Gary Watson, Mr. Patrick D. Cobb, Mr. Samuel L. Caster, Mr. Charles E. Fioretti and Mr. William C. Fioretti and Mannatech dated August 31, 1997, incorporated herein by reference to Exhibit 10.6 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.5 Form of Indemnification Agreement with a schedule of director signatories, incorporated herein by reference to Exhibit 10.8 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.6 Schedule of additional directors signatories relating to the Form of Indemnification Agreements in Exhibit 10.9 above, incorporated herein by reference to Exhibit 10.7 to Mannatech's Form 10-K (File No.000-24657) filed with the Commission on March 30, 2000.
- 10.7 Letter of Understanding Regarding Development of Proprietary Information for Mannatech effective as of August 1, 1997, as amended, by and between Mr. Bill H. McAnalley, Ph.D. and Mannatech, incorporated herein by reference to Exhibit 10.12 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.8 Commercial Lease Agreement dated November 7, 1996 between MEPC Quorum Properties II Inc. and Mannatech, as amended by the First Amendment thereto dated May 29, 1997 and the Second Amendment thereto dated November 13, 1997, incorporated herein by reference to Exhibit 10.13 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.9 Commercial Lease Agreement dated May 29, 1997 between MEPC Quorum Properties II Inc. and Mannatech, as amended by the First Amendment thereto dated November 6, 1997, incorporated herein by reference to Exhibit 10.14 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.10 Assignment of Patent Rights dated October 30, 1997 by and among Mr. Bill H. McAnalley, Ph.D., Mr. H. Reginald McDaniel, Mr. D. Eric Moore, Ms. Eileen P. Vennum and Mr. William C. Fioretti and Mannatech, incorporated herein by reference to Exhibit 10.15 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.11 Trademark License Agreement effective as of August 14, 1997 by and between Mannatech and Caraloe, Inc., incorporated herein by reference to Exhibit 10.19 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.12 Supply Agreement effective as of August 14, 1997 by and between Mannatech and Caraloe, Inc., incorporated herein by reference to Exhibit 10.17 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.13 Supply Agreement effective as of January 12, 2000 by and between Mannatech and Caraloe, Inc. incorporated herein by reference to Exhibit 10.7 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on March 30, 2000.
- 10.14 Letter of Agreement from Mannatech to Mr. Michael L. Finney of LAREX, Incorporated dated December 23, 1997, incorporated herein by reference to Exhibit 10.20 to Mannatech's Form S-1 (File No. 333- 63133) filed with the Commission on September 10, 1998.

- 10.15 Product Development and Distribution Agreement effective as of September 15, 1997 between New Era Nutrition Inc. and Mannatech, incorporated herein by reference to Exhibit 10.21 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.16 Summary of Management Bonus Plan, incorporated herein by reference to Exhibit 10.23 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.17 Individual Guaranty of Mr. Samuel L. Caster dated January 5, 1998, incorporated herein by reference to Exhibit 10.27 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.18 Individual Guaranty of Mr. Charles E. Fioretti dated January 5, 1998, incorporated herein by reference to Exhibit 10.28 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.19 Form of Employment Agreement to be entered into between Mannatech and each of Mr. Patrick D. Cobb, Mr. Anthony E. Canale, Mr. Bill H. McAnalley and Ms. Deanne Varner, incorporated herein by reference to Exhibit 10.30 to Mannatech's Amendment No. 1 to Form S-1 (File No. 333-63133) filed with the Commission on October 28, 1998.
- 10.20 Employment Agreement dated November 1, 1999, entered into between Mannatech and Mr. Terry L. Persinger, incorporated herein by reference to Exhibit 10.7 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on March 30, 2000.
- 10.21 Form of Employment Agreement entered into between Mannatech and Mr. Robert M. Henry, incorporated herein by reference to Exhibit 10.24 to Mannatech's Form 10-Q (File No. 000-24657) filed with the Commission on May 15, 2000.
- 10.22 Employment Agreement dated September 21, 2000, entered into between Mannatech and Mr. Charles E. Fioretti, incorporated herein by reference to Exhibit 10.22 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on April 2, 2001.
- 10.23 Employment Agreement dated February 19, 2001, entered into between Mannatech and Mr. C. Armando Contreras, incorporated herein by reference to Exhibit 10.23 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on April 2, 2001.
- 10.24 Renewal and Extension Promissory Note dated February 17, 1999 in the amount of \$33,316.02 made by Mr. Patrick D. Cobb, incorporated herein by reference to Exhibit 10.25 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on March 31, 1999.
- 10.25 Renewal and Extension Promissory Note dated February 17, 1999 in the amount of \$199,896.10 made by Mr. Samuel L. Caster incorporated herein by reference to Exhibit 10.26 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on March 31, 1999.
- 10.26 Renewal and Extension Promissory Note dated February 17, 1999 in the amount of \$199,896.09 made by Mr. Charles E. Fioretti incorporated herein by reference to Exhibit 10.27 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on March 31, 1999.
- 10.27 Consultancy Agreement dated June 1, 2000 by and between Mannatech, Incorporated and Mr. Samuel L. Caster incorporated herein by reference to Exhibit 10.25 to Mannatech's Form 10-Q (File No. 000-24657) filed with the Commission on August 14, 2000.
- 10.28 Lock-up Agreement and Promissory Note for \$500,000 between Mannatech and Mr. Charles E. Fioretti, dated August 8, 2000, incorporated herein by reference to Exhibit 10.27 to Mannatech's Form 10-Q (File No. 000-24657) filed with the Commission on August 14, 2000.
- 10.29 Separation Agreement dated February 28, 2001 with Mr. Anthony E. Canale, incorporated herein by reference to Exhibit 10.29 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on April 2, 2001.
- 10.30 Cancellation Agreement dated June 24, 1999, by and between Mannatech, Incorporated and Mr. Ray Robbins.\*

- 21 List of Subsidiaries, incorporated herein by reference to Exhibit 21 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on April 2, 2001.
- 23 Consent of PricewaterhouseCoopers LLP, incorporated herein by reference to Exhibit 23 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on April 2, 2001.

- ------

- \* Filed herewith.
  - (b) Reports on Form 8-K.

None.

(c) Item 601 Exhibits

The exhibits required by Item 601 of Regulation S-K are set forth in (a) 3 above.

(d) Financial Statement Schedules

The financial statement schedules required by Regulation S-K are set forth in (a) 2 above.

#### **SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dallas, State of Texas on April 24, 2001.

Mannatech, Incorporated

/s/ Robert M. Henry

By:

Robert M. Henry Chief Executive Officer and Director

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on April 24, 2001, on behalf of the registrant and in the capacities indicated.

Signature	Title
/s/ Robert M. Henry  Robert M. Henry	Chief Executive Officer and Director (principal executive officer)
/s/ Terry L. Persinger  Terry L. Persinger	President, Chief Operating Officer and Director
/s/ Stephen D. Fenstermacher Stephen D. Fenstermacher	Senior Vice President and Chief Financial Officer (principal accounting officer)
/s/ Charles E. Fioretti	Chairman of the Board
Charles E. Fioretti	_
/s/ Samuel L. Caster	Director
Samuel L. Caster	_
/s/ Anthony E. Canale	Director
Anthony E. Canale	_
/s/ Steven A. Barker Ph.D.	Director
Steven A. Barker Ph.D.	_
/s/ James M. Doyle, Jr.	Director
James M. Doyle, Jr.	_
/s/ Jules Zimmerman	Director
Jules Zimmerman /s/ Roger E. Beutner	Director
Roger E. Beutner	_

# INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

	Page
Annual Financial Statements:	
Report of Independent Accountants	
1998, 1999 and 2000	F-4
December 31, 1998, 1999 and 2000	F-5
2000 Notes to Consolidated Financial Statements	

#### REPORT OF INDEPENDENT ACCOUNTANTS

To the Board of Directors and Shareholders of Mannatech, Incorporated

In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations, of changes in shareholders' equity and of cash flows present fairly, in all material respects, the financial position of Mannatech, Incorporated and its subsidiaries at December 31, 1999 and 2000, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2000, in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Company's management; our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with auditing standards generally accepted in the United States of America, which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

As discussed in Note 1 of the Notes to Consolidated Financial Statements, the Company changed its method of accounting for revenue recognition as a result of the adoption of Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial Statements."

PricewaterhouseCoopers LLP

Dallas, Texas
February 27, 2001, except as to Note 8,
which is as of March 14, 2001

# 

	Decembe	
	1999	
ASSETS	*	
Cash and cash equivalents	\$11,576 1,388	\$ 5,736 
\$58 in 1999 and 2000	275  158	692 2,300 187
Inventories  Prepaid expenses and other current assets  Deferred tax assets	13,318 727 564	13,326 745 1,201
Total current assets	28,006 14,093 543	24,187 13,324 390 1,000
Total assets		\$38,902
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current portion of capital leases and note payable		
Accounts payable	1,892 13,721	4,309 12,288
Total current liabilities	16,345 325	16,898 27 500
Deferred tax liabilities	817	1,752
Total liabilities	17,487	
Commitments and contingencies (Note 13)		
Shareholders' equity: Preferred stock, \$0.01 par value, 1,000,000 shares		•
authorized, no shares issued and outstanding		
outstanding in 2000	2 17,347	•
Note receivable from shareholder	10,147	(167) 2,798
translation adjustment		(321)
Less treasury stock, at cost, 16,308 shares in 1999 and	27,496	20,262
122,128 shares in 2000 and a commitment to purchase common stock of \$1,000	(204)	(1,537)
Total shareholders' equity		18,725
Total liabilities, commitment to repurchase common stock and shareholders' equity	\$44,779 ======	\$38,902 =====

# CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except for per share information)

For the Year Ended December 31,

		cember 31,	
	1998	1999	2000
Net sales  Cost of sales  Commissions	27,140 66,650		27,088 61,743
Gross profit		102,697  77,033	
Operating expenses: Selling and administrative expenses Other operating costs Write-off of fixed asset Write-off of deferred offering costs	31,880 22,359  847	34,861 26,091	37,038 31,706 870
Total operating expenses		60,952	
Income (loss) from operations	16,057 (92) 53 299	16,081 (713) 150	(8,439) (684) 69 558
Income (loss) before income taxes and cumulative effect of accounting change	15,797 5,743	16,530	(8,382) (1,243)
Income (loss) before cumulative effect of accounting change			
Net income (loss)	\$ 10,054	\$ 10,788 ======	\$ (7,349)
Earnings (loss) per common shares Basic: Before cumulative effect of accounting change Cumulative effect of accounting change		\$ 0.45	
Net	\$ 0.45		\$ (0.30)
Earnings (loss) per common share Diluted: Before cumulative effect of accounting change Cumulative effect of accounting change	\$ 0.42	\$ 0.43	\$ (0.29) \$ (0.01)
Net	\$ 0.42	\$ 0.43 ======	
Weighted-average common shares outstanding: Basic	22,102	24,133 ======	24,946 ======
Diluted	23,659	25,224	24,946 ======
Dividends declared per common share	\$ 0.39 =====	\$ 0.06 =====	\$ ======

## CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

FOR THE YEARS ENDED DECEMBER 31, 1998, 1999 AND 2000 (in thousands, except per share information)

	Common stock		Common stock Additional Notes		Retained	Accumulated other	Treasury stock		Total shareholders'
	Shares	Par value		shareholders	earnings	income (loss)			equity
Balance at									
December 31, 1997 Dividends declared	22,102	\$ 2	\$ 2,632	\$ (636)	\$ (754)	\$		\$	\$ 1,244
(\$0.39 per share) Comprehensive income:					(8,615)				(8,615)
Net income					10,054				10,054
Balance at December 31, 1998 Dividends declared	22,102	2	2,632	(636)	685				2,683
(\$0.06 per share) Repayment of notes receivable					(1,326)				(1,326)
shareholders Net proceeds from				636					636
offering Exercise of	1,500		9,241						9,241
warrants Tax benefit from exercise of warrants	475		941						941
and stock options Tender of common stock for exercise			3,543						3,543
of stock options Proceeds from stock	133		204				16	(204)	
option exercises Comprehensive income:	564		786						786
Net income					10,788				10,788
Balance at December 31, 1999 Proceeds from stock	24,774	2	17,347		10,147		16	(204)	27,292
option exercises Tax benefit from exercise of warrants	261	1	362						363
and stock options Issuance of note receivable			240						240
shareholders Repayment of note receivable				(500)					(500)
shareholders Commitment to repurchase common	(106)			333			106	(333)	
stock from shareholder Comprehensive loss: Foreign currency								(1,000)	(1,000)
translation adjustment						(321)			(321)
Net loss					(7,349)				(7,349) 
Balance at December 31, 2000	24,929 =====	\$ 3 ======	\$17,949 ======	\$ (167) ======	\$ 2,798 ======	\$ (321) ======		\$(1,537) ======	\$ 18,725 ======

# CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)

	For the Yea		
	1998	1999	2000
Cash flows from operating activities:	t 10.0E4	ф 10 700	ф (7.240 <b>)</b>
Net income (loss)	\$ 10,054	\$ 10,788	\$ (7,349)
Depreciation and amortization	2,227	2,969	3,738
Write-off of fixed asset software Loss on disposal of assets	 2E2	 287	870 157
Tax benefit from exercise of stock	332	207	157
options exercised	 847	-,	240 
party Cumulative effect of accounting change,		125	
net of tax  Deferred income tax expense (benefit)  Changes in operating assets and	934	(790)	210 298
liabilities:		()	
Accounts receivableIncome tax receivable	437	(212)	(428) (2,174)
Inventories		(6,443)	
Prepaid expenses and other current assets	96	(281)	(23)
Other assets	(41)	(283)	230
Accounts payable	1, 193 3 523	(3,589) (1,342)	981 (1,393)
·			
Net cash provided by (used in) operating activities	18,070		(4,561)
Cash flows from investing activities: Acquisition of property and equipment Repayment by shareholders/related	(4,626)	(3,243)	(4,109)
parties		944	124
(Purchase) Maturities of investments and restricted cash	200	(2,294)	2,293
Net cash used in investing activities		(4,593)	
Cash flows from financing activities: Cash overdrafts			1,451
Payment of dividendsProceeds from the initial public	(9,937)		, 
offering Proceeds from stock options exercised		12,000 786	 363
Repayment of capital lease obligations	(301)	(663)	(541)
Advances to shareholder  Proceeds from warrants exercised		 641	(500) 
Payment of note payable		(190) (615)	
Deferred offering costs	(2,647)	(615)	
Net cash provided by (used in) financing activities	(12,941)	10,633	584
Effect of exchange rate changes on cash			
and cash equivalents  Net increase (decrease) in cash and cash			(171)
equivalents	703	10,812	(5,840)
Beginning of year	61		11,576
End of year		\$ 11,576	\$ 5,736
Supplemental disclosure of cash flow information:	¢ 2.640	¢ 2.004	\$ 200
Income taxes paid	=========	========	=======
Interest paid	\$ 109 ======		\$ 69 =====
Summary of non-cash investing and financing activities follows: Assets acquired through capital lease			
obligations	\$ 1,472 =======		\$ =======

Assets acquired through note payable	\$	436	\$		\$	
	======	====	=====	====	====	=====
Commitment to repurchase common stock						
from shareholder	\$		\$		\$	1,000
	======	====	=====	====	====	=====
Treasury shares received for the payment						
of note receivableshareholder	\$		\$		\$	333
	======	====	=====	====	====	=====

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

#### NOTE 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Mannatech, Incorporated (the "Company") was incorporated in the State of Texas on November 4, 1993 as Emprise International, Inc. Effective October 25, 1995, the Company changed its name to Mannatech, Incorporated. The Company, located in Coppell, Texas, develops and sells proprietary nutritional supplements and topical products through a network marketing system in the United States, Canada, Australia, the United Kingdom and Japan. Independent associates ("Associates") purchase products at wholesale prices for the primary purpose of selling to retail consumers or for personal consumption. In addition, Associates earn commissions on their downline growth and sales volume. The Company has eight wholly owned subsidiaries located throughout the world. The wholly owned subsidiaries are as follows:

Wholly-owned Subsidiary Name	Date Incorporated	Location of Subsidiary	Date Operations Began
Mannatech Australia Pty Limited	April 22, 1998	St. Leonards, Australia	October 1, 1998
Mannatech Limited	December 1, 1998	Republic of Ireland	No operations
Mannatech Ltd.	November 18, 1998	Basingstoke, Hampshire U.K.	November 15, 1999
Mannatech Payment Services Incorporated	April 11, 2000	Coppell, Texas	June 26, 2000
Mannatech Foreign Sales Corporation	May 1, 1999	Barbados	May 1, 1999
<pre>Internet Health Group, Inc. (ceased operations as of December 31, 2000)</pre>	May 7, 1999	Coppell, Texas	December 20, 1999
Mannatech Japan, Inc. Mannatech Limited	January 21, 2000 February 14, 2000	, ·	June 26, 2000 No operations

#### Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

#### Use of Estimates

In preparing consolidated financial statements in conformity with generally accepted accounting principles, management is required to make certain estimates and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses during the reporting periods. Actual results may differ from such estimates.

#### Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.

#### Accounts Receivable

At December 31, 2000, accounts receivable consist of the overpayment of consumption tax paid in Japan, a refund of value added tax from the United Kingdom and payments due from vendors for the purchase of raw material inventories offset by an allowance account for amounts that are deemed uncollectible.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (Continued)

At December 31, 1999, accounts receivable consist of the overpayment of a 1998 sales tax assessment, a refund of value added tax from the United Kingdom and payments due from vendors for the purchase of raw material inventories offset by an allowance account for amounts that are deemed uncollectible.

#### **Inventories**

Inventories consist of raw materials and finished goods and are stated at the lower of cost (using standard costs, which approximates average costs) or market.

#### Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation computed using the straight-line method over the estimated useful life of each asset. Expenditures for maintenance and repairs are charged to expense as incurred. The cost of property and equipment sold or otherwise retired and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying consolidated statements of operations.

Property and equipment are reviewed for impairment whenever an event or change in circumstances indicates the carrying amount of an asset or group of assets may not be recoverable. The impairment review includes a comparison of future cash flows expected to be generated by the asset or group of assets with its associated carrying value. If the carrying value of the asset or group of assets exceeds expected cash flows (undiscounted and without interest charges), an impairment loss is recognized to the extent the carrying amount of the asset exceeds its fair value. During 2000, the Company recorded an impairment loss of \$870,000 on fixed asset software.

#### Other Assets

Other assets consist primarily of deposits for building leases and a restricted term deposit in an Australian bank, of approximately \$99,000 at December 31, 1999 and \$84,000 at December 31, 2000. This term deposit matures every six months and is automatically renewed by the Company as security for the Australian building lease.

#### Accounts Payable

The Company records book overdrafts in its cash accounts as accounts payable. Accounts payable includes book overdrafts of \$1,450,623 at December 31, 2000.

#### Income Taxes

The Company accounts for income taxes using the asset and liability approach for financial accounting and reporting. In the event that differences between the financial reporting bases and the tax bases of the Company's assets and liabilities result in net deferred tax assets, the Company evaluates the probability of realizing the future benefits indicated by such assets. A valuation allowance is provided for a portion or all of the net deferred tax assets when it is more likely than not that such portion, or all of such deferred tax assets, will not be realized.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (Continued)

#### Revenue Recognition

The Company's revenues consist of sales from products sold, starter and renewal packs sold and shipping fees charged. Substantially all product sales are made to Associates at a published wholesale price. Net sales also reflect product returns and any related refunds. The Company also records a reserve for product returns based on historical experience.

The Company adopted Staff Accounting Bulletin No. 101 "Revenue Recognition in Financial Statements" ("SAB 101") in the fourth quarter of 2000. Under SAB 101, the Company recognizes revenue for product sales upon the receipt of the products by the Associates. As a result of adopting SAB 101, the Company recorded a charge of \$210,000, net of tax of \$126,000 for the cumulative effect of this change at January 1, 2000. Beginning in 2000, the Company deferred all revenues until the Associate receives the shipment. The change in accounting method would not have a material effect on the Statements of Operations in 1999 and 1998 if adopted in those periods.

The Company also defers revenue received from the sale of the starter and renewal packs, which is in excess of the average wholesale value of the individual items included in such packs. Such deferrals are amortized over a twelve-month period. Revenues from the packs are allocated between products and event admission, based on the proportionate average fair value of these items. Allocated event revenues contained in pack sales are amortized over a twelve-month period. As of January 1, 2001, the Company discontinued the inclusion of the event admission in the starter and renewal packs. Total net deferred revenue was \$845,000 and \$691,000 at December 31, 1999 and 2000, respectively.

#### Shipping and Handling Cost

In accordance with the Emerging Issues Task Force No. 00-10 "Accounting for Shipping and Handling Fees and Costs", the Company records freight and shipping revenues, collected from the Associate, as revenue. The Company records inbound freight and shipping costs as a part of cost of sales and the Company records shipping and handling costs associated with shipping products to its Associates as selling and administrative expenses in the accompanying consolidated financial statements. Total shipping and handling costs included in selling and administrative expense was approximately \$8.2 million, \$9.1 million and \$6.6 million for 1998, 1999 and 2000, respectively.

# Accounting for Stock-based Compensation

The Company uses Statement of Financial Accounting Standards No. 123 ("FAS 123"), "Accounting for Stock-Based Compensation," for stock-based compensation issued to nonemployees. FAS 123 require that stock-based compensation be measured by the fair value at the date of grant. The Company measures the cost of stock-based compensation issued to employees and directors under Accounting Principles Board Opinion 25, "Accounting for Stock Issued to Employees" ("APB 25"), and its related interpretations. The Company has provided pro forma disclosures, as required by FAS 123, in Note 12 for stock-based compensation accounted for under APB 25.

### Advertising Costs

Advertising and promotional expenses are included in selling and administrative expenses and are charged to operations when incurred. Advertising and promotional expenses were approximately \$3.8 million, \$3.6 million and \$5.3 million for 1998, 1999 and 2000, respectively. Literature and promotional items, called sales aids, are sold to Associates to support their sales efforts and are primarily included in inventories and charged to cost of sales when sold.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (Continued)

#### Research and Development Costs

The Company expenses research and development costs when incurred. Research and development costs related to specific clinical studies, quality assurance programs and new product development were approximately \$391,000, \$439,000 and \$392,000 in 1998, 1999 and 2000, respectively. Research and development costs related to conceptualizing new products, enhancing existing products, Food and Drug Administration compliance studies, general supplies, internal salaries and consulting fees were approximately \$3.4 million, \$3.6 million and \$4.4 million in 1998, 1999 and 2000, respectively. Salaries are included in selling and administrative expenses and all other research and development costs are included in other operating expenses in the accompanying consolidated financial statements.

#### Software Development Costs

The Company capitalizes qualifying costs related to the development of internal use software pursuant to Statement Of Position No. 98-1, "Accounting for the Costs of Computer Software Developed or Obtained for Internal Use" ("SOP 98-1"). SOP 98-1 requires capitalization of qualifying costs after the conceptual formulation stage has been completed. Such costs are amortized over the estimated useful life of the software, which is five years. Capitalized costs were approximately \$929,000, \$1.7 million and \$681,000 in 1998, 1999 and 2000, respectively. Amortization expense related to capitalized software was approximately \$346,000, \$528,000 and \$712,000 in 1998, 1999 and 2000, respectively.

#### Earnings (Loss) per Share

The Company calculates earnings (loss) per share pursuant to Statement of Financial Accounting Standards No. 128, "Earnings per Share" ("FAS 128"). FAS 128 requires dual presentation of basic and diluted earnings (loss) per share ("EPS") on the face of the consolidated statement of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS calculations are based on the weighted-average number of common shares outstanding during the period, while diluted EPS calculations are calculated using the weighted-average number of common shares and dilutive common share equivalents outstanding during each period.

#### Concentrations of Credit Risk

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash, cash equivalents, investments and receivables from related parties. The Company utilizes financial institutions that the Company considers to be of high credit quality. The Company believes its notes receivables from shareholders are fully collectible.

#### Fair Value of Financial Instruments

The fair value of the Company's financial instruments, including cash and cash equivalents, notes receivable, notes payable, capital leases and accrued expenses, approximate their recorded values due to their relatively short maturities.

# Foreign Currency Translation

The Australian and the United Kingdom subsidiaries' are limited service providers and their functional currency is the United States dollar. Nonmonetary assets and liabilities are translated at historical rates, monetary assets and liabilities are translated at exchange rates in effect at the end of the year, and revenues and expenses are translated at average exchange rates for the year. Translation (gains) and losses of Mannatech's foreign subsidiaries totaled approximately \$17,000 (\$176,000) and \$345,000 in 1998, 1999 and 2000 respectively, and are included, in other expense, in the consolidated statements of operations.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (Continued)

#### Accumulated Other Comprehensive Income (loss)

The Japan subsidiary conducts substantially all of its business in Japanese Yen; therefore, the Company considers the Japanese Yen as it's functional currency. Its subsidiary's assets and liabilities are translated into United States dollars at exchange rates existing at the balance sheet dates, revenues and expenses are translated at weighted-average exchange rates, and shareholders' equity and intercompany accounts are translated at historical exchange rates. The foreign currency translation adjustment is recorded as a separate component of shareholders' equity and is included as accumulated other comprehensive income (loss) as required under Statement of Financial Accounting Standards No. 130 "Reporting Comprehensive Income." Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from nonowner sources and includes all changes in equity during a period.

#### Commissions

Associates are paid commissions, which are based on direct and indirect commissionable sales, downline growth and training of Associates. Commissions are accrued when earned and generally paid at various times within the following month.

#### NOTE 2 INITIAL PUBLIC OFFERING

On February 12, 1999, the Company completed an initial public offering, (the "Offering") on the Nasdaq National Market under the symbol "MTEX." In the Offering, the Company and certain selling shareholders sold an aggregate of 3,056,016 shares of common stock, par value \$0.0001 per share, at a price of \$8.00 per share. Of the total shares sold, 1,500,000 were sold by the Company, yielding gross proceeds to the Company of \$12.0 million. The net proceeds to the Company were \$9,240,958 after deducting deferred offering costs related to legal, accounting and printing fees of approximately \$2.0 million, other costs of approximately \$406,000 and the fee to the placement agent involved in the Offering of approximately \$389,000, net of reimbursement of approximately \$91,000 of expenses by the placement agent.

The selling shareholders sold 1,556,016 shares of common stock, yielding gross proceeds of approximately \$12.4 million. The net proceeds paid to the selling shareholders were approximately \$12.0 million, after deducting the fee to the placement agent of approximately \$498,000.

#### NOTE 3 INVESTMENTS

The Company accounts for investments in accordance with the provisions of Statement of Financial Accounting Standards No. 115 "Accounting for Certain Investments in Debt and Equity Securities" ("FAS 115"). Under FAS 115, debt securities that have readily determinable fair values are to be classified in three categories: held-to-maturity, trading securities and available for sale. Investments that the Company has the intent and the ability to hold to maturity are carried at amortized cost. The amortized cost of debt securities classified as held-to-maturity and are adjusted for amortization of premiums and accretion of discounts. Realized gains and losses on sales of securities are included in other expense, net in the accompanying statements of operations.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

At December 31, 2000, investments consist of an obligation of a United States Government sponsored enterprise, of \$1,130, which matures in 2003 and is classified as held-to-maturity. At December 31, 1999, investments consist of obligations of United States Government sponsored enterprises, which are classified as held-to-maturity and include the following (in thousands):

Matures		Gross Unrealized Loss	Fair Value
01 year	\$ 756	(\$1) (\$2) (\$-)  (\$3) ===	\$1,387 \$ 754 \$ 150  \$2,291 =====

#### NOTE 4 INVENTORIES

	1999	2000
Raw materials\$ Finished goods less inventory reserve of \$166, in 2000		
	\$13,318	\$13,326

#### NOTE 5 PROPERTY AND EQUIPMENT

Property and equipment at December 31, 1999 and 2000 consist of the following (in thousands):

	Estimated			
	Useful Lives 19		1999	2000
Office furniture and equipment	3 to 5 5	years years	28	11,247 28
Less accumulated depreciation and			19,908	22,643
amortization			(6,162)	(9,319)
Construction in progress			13,746 347	13,324
			\$14,093 ======	\$13,324 ======

Gross capital leased assets of \$1.7 million were included in both the December 31, 1999 and 2000 balances, respectively, and relate to warehouse and laboratory equipment. In 1999, construction in progress consists of internally developed software and warehouse equipment.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

#### NOTE 6 ACCRUED EXPENSES

Accrued expenses at December 31, 1999 and 2000 consist of the following (in thousands):

	1999	2000
Commissions payable. Income taxes payable. Accrued royalties and compensation. Accrued inventory purchases. Accrued legal and accounting. Sales and other taxes payable. Deferred revenue. Customer deposits. Other accrued expenses.	35 2,062 3,121 625 875 845 418 1,722	\$ 3,598  1,874 1,024 1,522 776 691 1,219 1,584 

#### NOTE 7 NOTE PAYABLE

In 1999, the Company entered into an unsecured note payable of approximately \$436,000, with a finance company to finance its three-year product liability insurance premiums. The note bears interest at 8.0% and was payable in monthly installments of approximately \$16,000 through December 2000.

#### NOTE 8 CAPITAL LEASE OBLIGATIONS

In March and August 1998, the Company entered two new lease agreements totaling \$631,000 and \$841,000, respectively, with Banc One Leasing Corporation to fund the purchase of furniture and certain capital equipment for its laboratory facility and warehouse. The leases are collateralized by the leased assets, bear interest at 9.3%, are payable in thirty-six monthly installments and contain certain financial covenants which require the Company to maintain stated levels of debt to tangible net worth and an annual cash flow coverage ratio. At December 31, 2000, the Company was in violation of the annual cash flow ratio coverage covenant; however, a satisfactory waiver of this violation was received from the lender on March 14, 2001 that waived this violation at December 31, 2000.

The Company leases certain equipment under various capital leases agreements of approximately \$280,000. These agreements have terms that range from three to five years and contain either a bargain purchase option or a buyout provision that the Company intends to exercise. A summary of future minimum payments under capital lease agreements is as follows (in thousands):

	Year Ending December 31,
2001.         2002.	
Future minimum lease payments	
Less current portion of capital lease obligations	328 (301)
Capital lease obligations, excluding current portion	\$ 27 ====

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

#### NOTE 9 INCOME TAXES

The components of the Company's income (loss) before income taxes are attributable to the following jurisdictions for the years ended December 31 (in thousands):

	1998	1999	2000
United States			
	\$15,797	\$16,530	\$(8,382)
	======	======	======

The components of the Company's income tax provision for 1998, 1999 and 2000 were as follows:

	1998	1999	2000
Current provision:			
Federal	\$4,351	\$6,284	\$(1,827)
State	430	276	213
Foreign	28	(28)	73
	4,809	6,532	(1,541)
Deferred provision:			
Federal	853	(674)	451
State	81	(116)	(153)
	934	(790)	298
	\$5,743	\$5,742	\$(1,243)
	==		

	1998	1999	2000
Federal statutory income			
taxes	35.0%	35.0%	35.0%
of federal benefit	2.1	1.0	(0.1)
Difference between U.S. statutory rate and			
foreign rate	(1.4)	(1.0)	(7.8)
allowance			(11.0)
Nondeductible expenses	0.7	0.7	(1.0)
Other		(1.0)	(0.3)
	36.4%	34.7%	14.8%
	====	====	=====

At December 31, 2000, the Company had an income tax refund of \$2.3 million, which primarily contained federal tax net operating loss that will be carried back. The Company also had state tax net operating losses that are eligible to be carried forward and will begin to expire in various tax years.

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

Deferred taxes consisted of the following at December 31 (in thousands):

	1999	2000
Deferred tax assets: Current:		
Deferred revenue		\$ 255 327 322
Inventory reserve		61
State tax net operating loss carryforward Other		193 43
Total current deferred tax assets	564	1,201
Noncurrent:		024
Net operating loss carryforward for the Japan subsidiary  Compensation expense	82	
Start-up costs Capital loss carryforward		
Total noncurrent deferred tax assets	373	1,000
Total gross deferred tax assets		
Total net deferred tax assets		\$1,277 ======
Deferred tax liabilities: Noncurrent:		
Depreciation and amortization		\$1,828 =====

The valuation allowance represents a reserve against the deferred tax asset related to the Japan operating loss carryforward, which may not be fully realized.

The net deferred tax assets (liabilities) are classified in the accompanying consolidated financial statements as follows (in thousands):

	1999	2000
Current deferred tax assets		
Net deferred tax assets (liabilities)	\$(253) =====	\$ (551) ======

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (Continued)

#### NOTE 10 TRANSACTIONS WITH RELATED PARTIES AND AFFILIATES

On February 17, 1999, the Company signed notes receivable agreements with certain shareholders. The notes bear interest at 6.0%, with installments due annually through February 17, 2004. The total amount of such notes outstanding at December 31, 1999 and 2000 was approximately \$701,000 and \$577,000, respectively. The future maturities of notes receivables due from shareholders are as follows (in thousands):

	Year Ending December 31,
2001	\$187
2002	138
2003	141
2004	111
	577
Less current portion	(187)
Notes receivable due from shareholders, excluding current	
portion	\$390 ====

On December 31, 1997, the Company advanced \$284,000 to two officers and \$353,000 to two directors of the Company to pay taxes due in connection with the cancellation of their incentive compensation agreements. These advances were paid in full in February 1999.

In 1998, 1999 and 2000, the Company accrued commission expenses to a major shareholder and former executive officer, Mr. William C. Fioretti, of approximately \$121,000, \$453,000 and \$181,000 of which \$37,000 and \$27,000 remained unpaid at December 31, 1999 and 2000, respectively. During 1998, the Company also paid Mr. William Fioretti \$250,000 for various consulting activities related to new product development. During 1997, the Company advanced \$125,000 to Mr. William Fioretti's brother-in-law, which remained unpaid at December 31, 1998. During 1999, Mr. William Fioretti guaranteed these funds to the Company; however, in December 1999, the \$125,000 was written off by the Company as uncollectible.

On May 5, 2000 Mr. Samuel L. Caster resigned as President. On June 1, 2000, the Company entered into a consulting agreement with Mr. Caster. Under the terms of the agreement, the Company agreed to pay Mr. Caster \$50,000 each month plus automobile insurance and other expenses. During 2000, the Company paid Mr. Caster approximately \$312,000 of which \$50,000 remained unpaid at December 31, 2000.

On August 8, 2000, the Company loaned Mr. Charles E. Fioretti \$500,000. The loan was collateralized by 174,570 shares of Mr. Charles Fioretti's stock and is being repaid in six successive monthly installments of 26,455 shares of his common stock beginning on September 3, 2000 and continuing through February 3, 2001. During 2000, Mr. Charles Fioretti exchanged 105,820 shares of his stock to reduce the loan to him by \$333,000. As of December 31, 2000, the balance of the note receivable was \$167,000.

On August 8, 2000, the Company entered into a lockup and repurchase agreement with Mr. Charles Fioretti. Under the terms of the agreement, the Company agreed to buy \$1.0 million worth of his stock. The commitment to repurchase common stock reduced shareholders' equity on the balance sheet. On a monthly basis, beginning on March 3, 2001 and continuing through February 3, 2002, the Company agreed to buy \$83,333.33 worth of his stock, valued at 90% of the fair market value price on the close of that business day.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

Mr. Charles Fioretti is prohibited from selling any of his shares through March 2, 2002, unless approved by the Board of Directors. Beginning March 3, 2002, the Company will have the option, but not the obligation to repurchase on a monthly basis, at least \$100,000 worth of his stock, valued at the greater of 90% of the fair market value or \$2.00 per share. As long as the Company exercises this option, Mr. Charles Fioretti will be prohibited from selling any of his shares.

On December 29, 2000, the Board of Directors entered into a Separation Agreement with Mr. Anthony Canale. Under the terms of the agreement, Mr. Canale will remain a Director of the Company but will resign as Chief Operating Officer of International Operations as of February 28, 2001. The Company will pay Mr. Canale \$400,000 on March 1, 2001, \$250,000 on February 28, 2002 and \$250,000 on February 28, 2003. The Company will also continue to pay the lease payments for his car and are for any future consulting. On March 1, 2000, Mr. Canale will begin to receive \$2,500 for each Board of Director's meeting he attends, which is an amount set by the Board of Directors for his service to the Board and reimbursement for any expenses. Finally, the Company agreed to grant Mr. Canale a total of 213,333 warrants on March 1, 2001 at an exercise price ranging from \$1.75 to \$4.00, which vest on March 1, 2001 and are exercisable for seven years. As of December 31, 2000, the Company accrued \$950,000 relating to Mr. Canale and also accrued compensation of approximately \$140,000 related to the termination of various other officers.

#### NOTE 11 CANCELLATION OF INCENTIVE COMPENSATION AGREEMENTS

In April 1994, the Company entered into two incentive compensation agreements with Mr. Ray Robbins, an Associate, shareholder and advisory board member of the Company. The agreements and its subsequent amendments required the Company to pay compensation based on a specified monthly sales volume and increase in the admittance of new independent Associates. One of these agreements was subsequently canceled in 1997. In June 1999, the other incentive agreement was canceled by paying Mr. Robbins \$750,000. Of this amount, \$500,000 was paid at the time the agreement was canceled. The remaining \$250,000 is payable in monthly installments of \$10,000 over two years. These installments are non-interest bearing and are included in accrued expenses. The \$750,000 charge is included in other operating expenses in the 1999 consolidated financial statements. In 2000, the Company agreed to pay Mr. Robbins an additional \$200,000 related to the cancellation of his other incentive agreement, which was canceled in June 1999. During 1998, 1999 and 2000, the Company paid Mr. Robbins approximately \$120,000, \$618,000 and \$320,000, respectively related to the incentive agreement. Mr. Robbins also receives commissions from the Company for his product sales and downline growth.

#### NOTE 12 EMPLOYEE BENEFIT PLANS

#### Employee Retirement Plan

Effective May 9, 1997, the Company adopted a defined contribution 401(k) and Profit sharing plan (the "Plan"). The Plan covers all full-time employees who have completed three months of service and attained the age of twenty-one. Employees can contribute up to 20% of their annual compensation, but are limited to the maximum percentage allowable under the Internal Revenue Code. The Company will match 25% of the first 6% contributed and may also make discretionary contributions to the Plan, which may not exceed 100% of the first 15% of the employees annual compensation. Company contributions to employees vest ratably over a five-year period. During 1998, 1999 and 2000, the Company contributed, approximately \$93,000, \$150,000 and \$177,000, respectively, to the plan.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (Continued)

#### Stock Option Plans

In May 1997, the Board of Directors approved the 1997 Stock Option Plan (the "1997 Stock Option Plan"), which provides incentive and nonqualified stock options to employees and nonemployees, respectively. The Company reserved 2,000,000 shares of common stock for issuance pursuant to the 1997 Stock Option Plan. On October 19, 1999, 50,000 options were granted to a Director and vest over three years beginning October 19, 2000. No options granted under this plan will remain exercisable later than ten years after the date of grant.

In May 1998, the Board of Directors approved the 1998 Stock Option Plan (the "1998 Stock Option Plan") that provides incentive and nonqualified stock options to employees and nonemployees, respectively. The Company reserved 1,000,000 shares of common stock for issuance pursuant to the stock options granted under the 1998 Stock Option Plan. No options granted under this plan will remain exercisable later than ten years after the date of the grant.

In June 2000, the Board of Directors approved the 2000 Stock Option Plan (the "2000 Stock Option Plan") that provides incentive and nonqualified stock options to employees and nonemployees, respectively. The Company reserved 2,000,000 shares of common stock for issuance pursuant to the stock options granted under the 2000 Stock Option Plan. On August 23, 2000, 150,000 stock options were granted to three Directors and vest over three years beginning August 23, 2001. No options granted under this plan will remain exercisable later than ten years after the date of grant. At December 31, 2000, the 2000 Stock Option Plan had 290,000 shares available for grant by the Board of Directors.

Stock options outstanding for the 1997, 1998 and 2000 Stock Options Plans, (collectively, "the Stock Option Plans") are as follows:

	19	998	199	99	20	90
			Shares	Weighted Average Exercise Price	Shares	
Outstanding at beginning of						
year	1,600	\$ .45	2,343	\$3.53	2,255	\$5.39
Granted	743	8.00	677	7.81	1,795	2.62
Exercised			(715)	1.38	(261)	1.39
Canceled			(50)	8.00	(247)	3.14
Outstanding at end of year	2,343	\$3.53	2,255	\$5.39	3,542	\$4.44
Options exercisable at year						
end		\$	1,422	\$4.33	1,833	\$6.14
Weighted-average fair value of options granted during						
the year		\$2.20		\$3.03		\$1.81
		=====		=====		=====

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

The following table summarizes information with respect to options outstanding and exercisable at December 31, 2000:

		Options O	utstanding	Opti Exerci	
Exercise Price Range	of Shares	Average Exercise	Weighted Average Remaining Contractual Life (in years)	Number of Shares	Weighted Average Exercise Price
\$1.35 \$2.00 \$2.01 \$6.99		\$1.47 \$2.63	7 10	504 	\$1.45 \$0.00
\$7.00 \$8.00	,	\$7.91	8	1,329	\$7.91
\$1.35 \$8.00	3,542	\$4.44	9	1,833	\$6.14

During 1999, the Board of Directors of the Company's wholly-owned subsidiary, Internet Health Group, Inc.'s ("IHG"), approved its 1999 Incentive and Nonstatutory Stock Option Plan ("IHG Plan"). Under the IHG Plan, a total of 1,500,000 shares of IHG's common stock, par value \$0.0001 per share was reserved for issuance. During 1999, IHG granted 1,258,750 incentive stock options to various employees and to the executive officers of the Company. The stock options were exercisable at \$0.27 per share, which was the estimated fair value on the date of grant. As of December 31, 1999 none of these options were exercised or canceled. The weighted-average fair value of options granted during 1999 was \$0.15 per share. As of December 31, 2000, none of the IHG options were exercised.

Incentive stock options granted to employees are nontransferable and are granted for terms no longer than ten years at a price which may not be less than 100% of the fair value of the common stock on the date of grant. For purposes of pro forma disclosures, the estimated fair values of the options are amortized to expense over the vesting period. The Company's pro forma information follows (in thousands, except for per share information):

		1999	
Consolidated net income (loss)			
As reported	\$10,054	\$10,788	\$(7,349)
Pro forma			
Basic EPS		-	, ,
As reported	\$ 0.45	\$ 0.45	\$ (0.29)
Pro forma	\$ 0.44	\$ 0.42	\$ (0.33)
Diluted EPS			
As reported	\$ 0.42	\$ 0.43	\$ (0.29)
Pro forma	\$ 0.41	\$ 0.42	\$ (0.33)

The fair value of each option granted was estimated on the date of grant using the Black-Shoales option-pricing model with the following weighted-average assumptions during 1998, 1999 and 2000:

		1999	
Dividend yield	4%	0%	0%
Expected volatility	0%	47.7%	68.0%
Risk-free rate of return	5.4%	6.3%	5.8%
Expected life (in years)	6	6	7

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (Continued)

Under the Stock Option Plans, nonqualified stock options granted to nonemployees are valued using the fair value method, are nontransferable and are granted for terms no longer than six years and at a price which may not be less than 100% of the fair value of the common stock on the date of grant. During 1997, the Company issued 356,000 nonqualified stock options to nonemployees at an exercise price of \$1.35 per share. Additionally, the Company issued 100,000 nonqualified stock options in July 1997. These options are priced at \$2.00, vest immediately, are exercisable after one year and have a term of six years. During 1999 and 2000, 120,000 and 230,000 of these nonqualified options were exercised at an exercise price of \$1.35.

During 1997, the Company granted a consulting firm 475,015 warrants to purchase the same number of shares of the Company's common stock. These warrants were nontransferable and vested as follows: 178,125 shares at issuance and 26,990 each month through March 1, 1998. The warrants were exercisable at \$1.35 per share and were to expire on the earlier of May 1, 2003 or thirty-six months after the underlying shares were registered for public resale under the Securities Act. In February 1999, all of these warrants were exercised.

#### NOTE 13 COMMITMENTS AND CONTINGENCIES

The Company leases certain office space, automobiles and equipment under various noncancelable-operating leases, and has options to renew and renegotiate most of the leases. The leases expire at various times through January 2008. The Company also leases equipment under various month-to-month cancelable operating leases. Total rent expense was approximately \$1.2 million, \$1.6 million and \$2.4 million in 1998, 1999 and 2000, respectively.

Approximate future minimum rental commitments for the operating leases are as follows (in thousands):

		r Ending ember 31,
2001	\$	1,839
2002		1,270
2003		925
2004		759
2005		736
Thereafter		876
	\$	6,405
	===	=======

Effective September 1, 1998, the Company entered into various employment agreements with five of its executives. The employment agreements are for five years with a specified minimum salary and are extended automatically each year for one additional year unless both parties agree to termination prior to the end of any term. On November 1, 1999, the Company entered into an employment agreement with another one of its executives. This agreement expires in October 2002. Either party can cancel the agreements; however, if canceled by the Company, without cause, the Company is required to pay the minimum salary for the life of the agreement. In 2000, one of the five-year employment agreements, dated September 1, 1998, was canceled and replaced with a new three-year employment contract for his change in duties. In 2000, an employment agreement was entered into which expires on March 31, 2003. Either party can cancel this agreement; however, if canceled without cause, by the Company, the Company is required to pay the minimum salary for the life of the agreement.

The Company had a commitment with a supplier to purchase raw materials through August 2000. On January 12, 2000, the Company extended this commitment for an additional two years. In February 2001, the

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (Continued)

Company modified the agreement to reduce the purchase commitment. The purchase commitment with this supplier is approximately \$5.0 million, for both 2001 and 2002, respectively.

The Company utilizes royalty agreements with individuals or entities to provide compensation for items such as reprints of articles or speeches relating to the Company, sales of promotional videos featuring sports personalities and promotional efforts in product sales or attracting new Associates. From 1997 until August 1998, the Company paid a monthly fee of \$20,000 to a research foundation for promoting and conducting health studies of Associates. The total expenses for all of these agreements were approximately \$933,000, \$416,000 and \$459,000 in 1998, 1999 and 2000, respectively.

In October 1999, the Company entered into an agreement with a high level Associate, shareholder and advisory board member whereby the Associate would promote the Company and develop downline growth in Japan. Under the terms of the agreement, the Company agreed to pay the Associate \$50,000 a month plus all expenses for two years. The Associate can also earn additional commissions, up to \$1.6 million, for the development and sale of training materials and sales aids. During 1999, the Company accrued \$206,000 of which \$106,000 remained unpaid at December 31, 1999. During 2000, the Company accrued \$850,000 of which \$50,000 remained unpaid at December 31, 2000.

#### NOTE 14 CAPITAL TRANSACTIONS

#### Preferred Stock

On April 8, 1998, the Company amended its Articles of Incorporation to reduce the number of authorized shares of common stock from 100.0 million to 99.0 million. Additionally, the Company has authorized 1.0 million shares of preferred stock with a par value of \$0.01 per share. No shares of preferred stock have been issued or are outstanding.

#### Treasury Stock

During 1999, three of the Company's existing shareholders tendered 16,308 shares of their common stock, to the Company, at the current market price on the date of transfer.

During 2000, the Company loaned Mr. Charles E. Fioretti \$500,000 that was repaid, in part, by Mr. Fioretti tendering 105,820 shares of his common stock, to the Company, at the fixed price of \$3.15 per share, which was the current market price on the date of the note receivable.

### NOTE 15 LITIGATION

On May 30, 2000, the Company filed suit for breach of contract in the United States District Court of the Northern District of Texas, Dallas Division, against Gryphon Advisors II, L.L.C., a Delaware limited liability company. The Company alleged amounts billed for out-of-pocket expenses and advisory service fees totaling \$1.6 million were unreasonable and that Gryphon Advisors breached the advisory agreement. Under the advisory agreement, Gryphon was to provide advice on potential financing opportunities, acquisitions, the financial management of the Company, all aspects of its capital structure, capital-raising transactions and to assist the Company in evaluating potential acquisition targets. On June 26, 2000, Gryphon Advisors filed a cross-action suit for breach of contract and fraud seeking the payment of \$1.6 million and exemplary damages. On March 1, 2001, the Company and Gryphon Advisors agreed to dismiss its respective claims with prejudice and the Company agreed to pay Gryphon Advisors \$650,000 over a 12-month period.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (Continued)

The Company has several other pending claims incurred in the normal course of business which, in the opinion of management, can be resolved without material affect on the Company's consolidated results of operations or consolidated financial condition.

#### NOTE 16 EARNINGS PER SHARE

The following data show the amounts used in computing earnings (loss) per share and the effect on the weighted-average number of shares of dilutive common share equivalents (in thousands, except for per share information).

	1998			1999			2000		
	Income (Numerator)	Shares (Denominator)	Per Share Amount	Income (Numerator)	Shares (Denominator)	Per Share Amount	Loss (Numerator)	Shares (Denominator)	Per Share Amount
Basic EPS Net income (loss) available to Common Shareholders Effect of dilutive	\$10,054	22,102	\$ 0.45	\$10,788	24,133	\$ 0.45	(\$7,349)	24,946	(\$0.30)
Securities: Stock options Stock warrants		1,293 264		 	1,091		 	 	
Diluted EPS Net income (loss) available to common shareholders plus assumed conversions	\$10,054	23,659	\$ 0.42	\$10,788	25, 224	\$ 0.43	(\$7,349)	24,946	(\$0.30)
COUNCI STOUS	======	=====	=====	======	=====	=====	(ψ1,349) ======	=====	======

At December 31, 1999, 1.4 million common stock options were excluded from the dilutive EPS calculation and at December 31, 2000 all 3.5 million common stock options were excluded from the dilutive EPS calculation, as their effect was antidilutive.

## NOTE 17 ASSET IMPAIRMENT LOSS

In accordance with Statement of Financial Accounting Standards No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of," the Company recorded an impairment loss of \$870,000 as it determined the Internet Health Group, Inc., fixed asset software provided no future benefit.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)

## NOTE 18 SEGMENT INFORMATION

The Company conducts its business within one industry segment. No single Associate accounted for more than 10% of total sales for the years ended December 31, 1998, 1999 and 2000.

Long-lived assets by country for the years ended December 31, 1998, 1999 and 2000 were as follows (in millions):

	Country	1999	2000
Canada		 \$ 0.9 \$ 0.5 \$ \$ 15.4	\$ 0.6 \$ 0.4 \$ 1.2

Net sales (in millions and as a percentage of net sales) by country for the years ended December 31, 1998, 1999 and 2000 were as follows:

Year	United States	Canada	Australia	United Ki	ngdom Japan
1998	\$135.9 82.5%	\$26.8 16.1%	\$ 2.2 1.4%	\$	% \$%
1999	\$137.9 76.7%	\$25.7 14.3%	\$15.8 8.8%	\$ 0.3	0.2% \$%
2000	\$115.7 77.0%	\$20.2 13.5%	\$ 8.5 5.7%	\$ 1.9	1.3% \$3.7 2.5%

- 3.1 Amended and Restated Articles of Incorporation of Mannatech dated May 19, 1998, incorporated herein by reference to Exhibit 3.1 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on October 28, 1998.
- 3.2 Amended and Restated Bylaws of Mannatech dated April 27, 1999, incorporated herein by reference to Exhibit 4.3 to Mannatech's Form S-1 (File No. 333-77227) filed with the Commission on April 28, 1999.
- 3.3 First Amendment to the Bylaws of Mannatech dated October 20,1999, incorporated herein by reference to Exhibit 3.4 to Mannatech's Form 10-Q (File No. 000-24657) filed with the Commission on August 14, 2000.
- 3.4 Second Amendment to the Bylaws of Mannatech dated February 22, 2000, incorporated herein by reference to Exhibit 3.4 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on April 2, 2001.
- 3.5 Third Amendment to the Bylaws of Mannatech dated March 6, 2000, incorporated herein by reference to Exhibit 3.5 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on April 2, 2001.
- 3.6 Fourth Amendment to the Bylaws of Mannatech dated November 17, 2000, incorporated herein by reference to Exhibit 3.6 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on April 2, 2001.
- 4.1 Specimen Certificate representing Mannatech's common stock, par value \$0.0001 per share, incorporated herein by reference to Exhibit 4.1 to Mannatech's Amendment No. 1 to Form S-1 (File No. 333-63133) filed with the Commission on October 28, 1998.
- 10.1 1997 Stock Option Plan dated May 20, 1997, incorporated herein by reference to Exhibit 10.1 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.2 1998 Incentive Stock Option Plan dated April 8, 1998, incorporated herein by reference to Exhibit 10.2 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.3 2000 Option Plan dated June 19, 2000, incorporated herein by reference to Exhibit 10.26 to Mannatech's Form 10-Q (File No. 000-24657) filed with the Commission on November 14, 2000.
- 10.4 Exchange Agreement by and among Mr. Gary Watson, Mr. Patrick D. Cobb, Mr. Samuel L. Caster, Mr. Charles E. Fioretti and Mr. William C. Fioretti and Mannatech dated August 31, 1997, incorporated herein by reference to Exhibit 10.6 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.5 Form of Indemnification Agreement with a schedule of director signatories, incorporated herein by reference to Exhibit 10.8 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.6 Schedule of additional directors signatories relating to the Form of Indemnification Agreements in Exhibit 10.9 above, incorporated herein by reference to Exhibit 10.7 to Mannatech's Form 10-K (File No.000-24657) filed with the Commission on March 30, 2000.
- 10.7 Letter of Understanding Regarding Development of Proprietary Information for Mannatech effective as of August 1, 1997, as amended, by and between Mr. Bill H. McAnalley, Ph.D. and Mannatech, incorporated herein by reference to Exhibit 10.12 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.8 Commercial Lease Agreement dated November 7, 1996 between MEPC Quorum Properties II Inc. and Mannatech, as amended by the First Amendment thereto dated May 29, 1997 and the Second Amendment thereto dated November 13, 1997, incorporated herein by reference to Exhibit 10.13 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.

1

- 10.9 Commercial Lease Agreement dated May 29, 1997 between MEPC Quorum Properties II Inc. and Mannatech, as amended by the First Amendment thereto dated November 6, 1997, incorporated herein by reference to Exhibit 10.14 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.10 Assignment of Patent Rights dated October 30, 1997 by and among Mr. Bill H. McAnalley, Ph.D., Mr. H. Reginald McDaniel, Mr. D. Eric Moore, Ms. Eileen P. Vennum and Mr. William C. Fioretti and Mannatech, incorporated herein by reference to Exhibit 10.15 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.11 Trademark License Agreement effective as of August 14, 1997 by and between Mannatech and Caraloe, Inc., incorporated herein by reference to Exhibit 10.19 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.12 Supply Agreement effective as of August 14, 1997 by and between Mannatech and Caraloe, Inc., incorporated herein by reference to Exhibit 10.17 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.13 Supply Agreement effective as of January 12, 2000 by and between Mannatech and Caraloe, Inc. incorporated herein by reference to Exhibit 10.7 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on March 30, 2000.
- 10.14 Letter of Agreement from Mannatech to Mr. Michael L. Finney of LAREX, Incorporated dated December 23, 1997, incorporated herein by reference to Exhibit 10.20 to Mannatech's Form S-1 (File No. 333- 63133) filed with the Commission on September 10, 1998.
- 10.15 Product Development and Distribution Agreement effective as of September 15, 1997 between New Era Nutrition Inc. and Mannatech, incorporated herein by reference to Exhibit 10.21 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.16 Summary of Management Bonus Plan, incorporated herein by reference to Exhibit 10.23 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.17 Individual Guaranty of Mr. Samuel L. Caster dated January 5, 1998, incorporated herein by reference to Exhibit 10.27 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.18 Individual Guaranty of Mr. Charles E. Fioretti dated January 5, 1998, incorporated herein by reference to Exhibit 10.28 to Mannatech's Form S-1 (File No. 333-63133) filed with the Commission on September 10, 1998.
- 10.19 Form of Employment Agreement to be entered into between Mannatech and each of Mr. Patrick D. Cobb, Mr. Anthony E. Canale, Mr. Bill H. McAnalley and Ms. Deanne Varner, incorporated herein by reference to Exhibit 10.30 to Mannatech's Amendment No. 1 to Form S-1 (File No. 333-63133) filed with the Commission on October 28, 1998.
- 10.20 Employment Agreement dated November 1, 1999, entered into between Mannatech and Mr. Terry L. Persinger, incorporated herein by reference to Exhibit 10.7 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on March 30, 2000.
- 10.21 Form of Employment Agreement entered into between Mannatech and Mr. Robert M. Henry, incorporated herein by reference to Exhibit 10.24 to Mannatech's Form 10-Q (File No. 000-24657) filed with the Commission on May 15, 2000.
- 10.22 Employment Agreement dated September 21, 2000, entered into between Mannatech and Mr. Charles E. Fioretti, incorporated herein by reference to Exhibit 10.22 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on April 2, 2001.
- 10.23 Employment Agreement dated February 19, 2001, entered into between Mannatech and Mr. C. Armando Contreras, incorporated herein by reference to Exhibit 10.23 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on April 2, 2001.

- 10.24 Renewal and Extension Promissory Note dated February 17, 1999 in the amount of \$33,316.02 made by Mr. Patrick D. Cobb, incorporated herein by reference to Exhibit 10.25 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on March 31, 1999.
- 10.25 Renewal and Extension Promissory Note dated February 17, 1999 in the amount of \$199,896.10 made by Mr. Samuel L. Caster incorporated herein by reference to Exhibit 10.26 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on March 31, 1999.
- 10.26 Renewal and Extension Promissory Note dated February 17, 1999 in the amount of \$199,896.09 made by Mr. Charles E. Fioretti incorporated herein by reference to Exhibit 10.27 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on March 31, 1999.
- 10.27 Consultancy Agreement dated June 1, 2000 by and between Mannatech, Incorporated and Mr. Samuel L. Caster incorporated herein by reference to Exhibit 10.25 to Mannatech's Form 10-Q (File No. 000-24657) filed with the Commission on August 14, 2000.
- 10.28 Lock-up Agreement and Promissory Note for \$500,000 between Mannatech and Mr. Charles E. Fioretti, dated August 8, 2000, incorporated herein by reference to Exhibit 10.27 to Mannatech's Form 10-Q (File No. 000-24657) filed with the Commission on August 14, 2000.
- 10.29 Separation Agreement dated February 28, 2001 with Mr. Anthony E. Canale, incorporated herein by reference to Exhibit 10.29 to Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on April 2, 2001.
- 10.30 Cancellation Agreement dated June 24, 1999, by and between Mannatech, Incorporated and Mr. Ray Robbins.\*
- List of Subsidiaries, incorporated herein by reference to Exhibit 21 to 21 Mannatech's Form 10-K (File No. 000-24657) filed with the Commission on April 2, 2001.
- Consent of PricewaterhouseCoopers LLP, incorporated herein by reference to Exhibit 23 to Mannatech's Form 10-K (File No. 000-24657) filed with 23 the Commission on April 2, 2001.

<sup>\*</sup> Filed herewith.

June 24, 1999

Mr. Ray Robbins, Individually and as President of Robbins Enterprises, Inc. 2201 Ingleside Grand Prairie, Texas 75050

RE: Buyback of Training Bonus Agreement by Mannatech, Incorporated Dear Mr. Robbins:

This letter is to document the agreement between Mannatech, Incorporated ("Mannatech") and yourself (whether acting individually or on behalf of Robbins Enterprises, Inc., a Texas corporation which you control) (collectively, "Robbins") with regard to the repurchase of certain rights that you have to payments from Mannatech under an agreement dated March 23, 1995 between Robbins and Emprise International, now know as Mannatech ("March 1995 Agreement").

Under the terms of the March 1995 Agreement, as stated in Paragraph 3(d) thereof, you are entitled to receive training payments as specified therein ("Training Payments"). At the time that the March 1995 Agreement was entered into between the parties, Mannatech was a fledgling, domestic company. Mannatech, today, has grown significantly, operates in two foreign countries, and contemplates further international expansion. Robbins contends that the March 1995 Agreement entitles him to Training Payments respecting international business. The Company has taken the position that the March 1995 Agreement entitled Robbins only to business that was contemplated at the time of the agreement, such being respecting domestic and Canadian business. In order to settle this difference of opinion, Mannatech has offered to repurchase of the rights to Training Payments, whether based on foreign or domestic business, to which Robbins has agreed ("Repurchase Agreement"). Robbins, hereafter in corporate literature and presentations, will be referred to as a "founder" of Mannatech.

The total amount of the Purchase Price for the Repurchase Agreement shall be the sum of \$750,000.00 which shall be paid part in cash upon the execution of this Letter Agreement, with the balance being paid by an earnout. Upon the execution of this Letter Agreement, Mannatech shall tender, in good funds, the sum of \$500,000.00 to Robbins as the Cash Portion of the Purchase Price of the Repurchase Agreement. As of the date of the execution of this Letter Agreement and

the receipt by him of the Cash Portion of the Purchase Price of the Repurchase Agreement, Robbins shall no longer be entitled to payments under the March 1995 Agreement, which shall in all respects be terminated as of that date. Robbins shall, thereafter be entitled to the Earnout Portion of the Purchase Price in an aggregate amount of \$250,000.00, payable as follows:

The Earnout Portion of the Purchase Price of the Repurchase Agreement shall be \$250,000. On or before the thirtieth day of each month, commencing in July, 1999, and continuing on the same date of each subsequent month thereafter until July, 2001 Mannatech shall pay the sum of \$10,000 ("Monthly Payment Amount") to Robbins. Accordingly, Robbins shall receive and continue to receive the Monthly Payment Amount until such time as the Earnout Portion of the Purchase Price shall have been paid in full. No interest shall accrue or be payable on the Earnout Portion of the Purchase Price of the Repayment Agreement.

Robbins and Mannatech have previously entered into an agreement to terminate certain of the rights of Robbins, excluding the rights to receive Training Payments. This agreement, dated May 14, 1997 is attached hereto as Combined Exhibit "A" ("May 1997 Agreement"). The May 1997 Agreement terminated all prior agreements between the parties except that one covenant in the March 1995 Agreement requiring Mannatech to pay Training Payments to Robbins which remained in effect. Except as modified by this Letter Agreement, resulting in the termination of Training Payments to Robbins by Mannatech, the May 1997 Agreement shall remain in full force and effect and valid in every way.

As a further inducement for Mannatech to enter into this Letter Agreement, Robbins, on behalf of himself and Robbins Enterprises, Inc. represents and warrants as follows:

- (a) That Robbins is the sole owner of the right to receive Training Payments, as currently continues to exist under the March 1995 Agreement, and that he has not transferred, assigned, pledged or impaired in any his right to transfer these rights back to Mannatech.
- (b) That upon the execution of this Letter Agreement, which shall operate as an Assignment to Mannatech, Mannatech shall have all and full right, title and interest in and to the Robbins Training Payment rights to the effect that neither he, nor any person, nor any entity shall have any right or claim of right to receive such Training Payments.
- (c) That there are, and will be at closing, no adverse or other claims to receipt of or title to the Training Payments, except as made by Robert Hydeman in his arbitration case against Robbins and Mannatech ("Hydeman Arbitration"), which claims shall have been settled or shall be settled contemporaneously with the execution of this Letter Agreement, nor will Robbins be upon notice of any threat of the same. And otherwise, no party shall have been granted any form of other right relating to receipt or right to receive the Training Payments. As of the execution and delivery by Robbins of this Letter Agreement, there will not be any action, suit or proceeding pending, or to the knowledge of the Robbins threatened, against or affecting the Training Payments or any portion thereof. All judicial proceedings concerning the Training Payments or any other dispute arising

from, inter alia, the Hydeman Arbitration will be finally dismissed, and terminated prior to or contemporaneously with the execution and delivery by Robbins of this Letter Agreement.

- (d) That Robbins is not currently in violation of or subject to any existing, pending or threatened investigations or inquiry by any governmental authority or to any remedial obligations under any applicable law.
- (e) That from and after the date hereof, up to and including the date upon which Robbins executes this Letter Agreement and receives the Cash Portion of the Purchase Price of the Repurchase Agreement, which in all events shall be prior to June 30, 1999, Robbins shall not sell, assign or create any right, title or interest whatsoever in or to the Training Payments, create or permit to exist any liens, encumbrances or charges thereon, without promptly discharging the same.
- (f) That Robbins shall properly pay, when due any tax liability resulting from and due any taxing authority on account of the effect of this Letter Agreement, and shall indemnify and hold Mannatech harmless from the same. Robbins further represents and warrants that he is an independent contractor of Mannatech for all purposes, including for federal and state income and other tax purposes.

All of the representations, warranties, covenants, agreements and indemnities of Seller and Purchaser contained in this Agreement, to the extent not performed at the Closing, shall survive the Closing and shall not be deemed to merge upon the acceptance of the Deed of Purchaser.

This Letter Agreement embodies and constitutes the entire understanding between the parties with respect to the transactions contemplated herein, and all prior or contemporaneous agreements, understandings, representations and statements (oral or written) are merged into this Letter Agreement, except as otherwise stated as to the survival of the effect of the May 1997 Agreement. The foregoing notwithstanding, nothing in this Letter Agreement shall be deemed to alter or amend any Associate Agreement of Robbins which creates an Associate position in the Mannatech downline, the obligation of Mannatech to reimburse or pay Robbins' reasonable travel expenses in connection with Mannatech business or to permit him to designate as Presidential to permit him to designate as Platinum Presidential (or the then highest rank of Mannatech Association position) the Top Gun associate position (Associate Control Number 727), reserving the right to designate at any later date the Duree/REI associate position (Associate Control Number 6103) and the Auge/REI associate position (Associate Control Number 994) as Platinum Presidential (or the then highest rank of Mannatech Associate position), provided such designation will not economically affect any Associate, rather only Mannatech. None of the terms of this Letter Agreement or any provision hereof may be waived, modified, amended, discharged or terminated except by an instrument in writing signed by the party against whom the enforcement of such waiver, modification, amendment, discharge or termination is sought, and then only to the extent set forth in such

This Letter Agreement is for the sole benefit of Robbins and Mannatech, its successors and  $\,$ 

assigns, and no other person shall be deemed to have any privity of contract hereunder, nor shall any other person be deemed to be a third party beneficiary hereunder.

This Agreement shall be governed by and construed in accordance with the laws of the State of Texas.

This Letter Agreement shall be binding upon and shall inure to the benefit of the parties and their respective heirs, executors, administrators, legal representatives, successors, and assigns.

All references to the date of this Agreement or similar references shall be deemed to refer to the date, in point of time, on which the Seller and Purchaser have executed a copy of this Agreement, which shall be not later than June 30, 1999.

With respect to the provisions of this Agreement, time is of the essence. However, if the final date of any period which is set out in any provision of this Agreement falls on a Saturday, Sunday or legal holiday under the laws of the United States, the State of Illinois or the State of Texas, then the time of such period shall be extended so that the last day of such period falls on the next day which is not a Saturday, Sunday or legal holiday.

The offer to repurchase the Training Payments upon the terms and conditions set forth herein which is extended to Robbins by delivery of this Agreement to him shall expire and be automatically revoked and cancelled unless he shall have executed this Agreement and delivered at least one (1) copy to Seller on or before 1:00 P.M. on June 30, 1999.

Very truly yours,

MANNATECH, INCORPORATED

By: /s/ Anthony E. Canale

Its: Chief Operating Officer

.ts. Chief Operating Officer

Agreed as of the 30th of June, 1999

/s/ Ray Robbins

Ray Robbins, Individually and on behalf or Robbins Enterprises, Inc., a Texas Corporation.

4

#### Exhibit A

#### AGREEMENT

This Agreement ("Agreement") is made and effective this 14th day of May, 1997, by and between Mannatech, Incorporated ("Corporation"), a Texas corporation whose principal place of business is 600 S. Royal Lane, Suite 200, Coppell, Texas and Ray Robbins ("Consultant"), who resides at 2201 Ingleside, Grand Prairie, TX 75050.

#### WITNESSETH:

WHEREAS, the Corporation is in the business of operating a network marketing company which sells a proprietary line of dietary supplements, cosmetics and over-the-counter drugs ("Products") and which compensates its distributors ("Associates") by a defined compensation plan;

WHEREAS, in connection with the development of its business the Corporation has entered into a confidential relationship with the Consultant whereby the Consultant will acquire or has acquired an intimate knowledge of the Corporation's business and will obtain or has obtained specialized skills. The Corporation will permit or has permitted the Consultant to have access to and to utilize the business goodwill, cost and pricing information, CONFIDENTIAL INFORMATION (as defined herein) and various trade secrets of the Corporation, including without limitation, marketing programs, business relationships, customer lists, and other compilations of information developed by the Corporation and essential to its business;

WHEREAS, the Consultant is a key to the business of the Corporation and the Corporation will provide or has provided the Consultant with access to such CONFIDENTIAL INFORMATION and trade secrets in reliance upon the Consultant entering into this Agreement; and

WHEREAS, in conjunction with the Consultant's access to and use of the CONFIDENTIAL INFORMATION and trade secrets of the Corporation, the Consultant has agreed to enter into this Agreement with the Corporation;

WHEREAS, the Consultant and the Corporation have previously entered into a series of Agreements, attached hereto as Compiled Exhibit "A" ("Prior Agreements"), which the parties now desire to modify by this Agreement;

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein and upon the terms, conditions and provisions hereinafter set forth, the Corporation and the Consultant do hereby agree as follows:

# ARTICLE I CONFIDENTIAL INFORMATION

- 1. The Corporation will provide or has provided the Consultant with specialized information concerning the products and the business operations of the Corporation. Irrespective of the term of consultancy, and in consideration of the Consultant's promises specified in Article II of this Agreement, the Corporation agrees to provide specialized training and instruction to the Consultant for the duties in consultation to the Corporation concerning the development of the Associate downline of the Corporation, recruitment and other matters as may come before the parties from time-to-time, and agrees to provide specialized training to the Consultant for such additional consulting duties as the parties may in good faith agree in the future.
- 2. During the course of the Consultant's engagement and training incident thereto the Consultant will be or was given access to the Corporation's CONFIDENTIAL INFORMATION concerning Products and the business operations of the Corporation.
- 3. The Consultant acknowledges that in the further course of the Consultant's engagement with the Corporation, the Consultant will gain a close, personal and special influence with the Corporation's customers and Associates and will be acquainted with all of the Corporation's business, particularly the Corporation's CONFIDENTIAL INFORMATION concerning the business of the Corporation and its affiliates.
- 4. For purposes of this Agreement "CONFIDENTIAL INFORMATION" shall mean and include information disclosed to the Consultant or known by the Consultant through the Consultant's engagement with the Corporation, not generally known in the Corporation's industry, about the Corporation's products, processes and services, including but not limited to information concerning inventions, trade secrets, research and development, as well as all data or information concerning customers (including, Associates), customer lists (including downline reports and similar reports of business activities and relevant information concerning persons who conduct the same), prospect lists, mailing lists, sales leads, contracts, financial reports, sales, purchasing, price lists, product costs, marketing programs, marketing plans, business relationships, business methods, accounts payable, accounts receivable, accounting procedures, control procedures and training materials.
- 5. The Consultant recognizes that the Consultant's position with the Corporation is one of the highest trust and confidence by reason of the Consultant's access to the CONFIDENTIAL INFORMATION and the Consultant agrees to use the Consultant's best efforts and will exercise utmost diligence to protect and safeguard the CONFIDENTIAL INFORMATION. In this respect, the Consultant agrees that fulfilling the obligations of the Agreement is part of the Consultant's job responsibilities with the Corporation for which the Consultant has been retained as an Consultant and for which the Consultant has received consideration therefor.

- 6. Except as may be required by the Corporation in connection with and during the Consultant's engagement with the Corporation, or with the express written permission of the Corporation, the Consultant shall not, either during the Consultant's work as an consultant with the Corporation or at any time thereafter, directly or indirectly, download, printout, copy, remove from the premises of the Corporation, use for the Consultant's own benefit or for the benefit of another, or disclose to another, any CONFIDENTIAL INFORMATION of the Corporation, its customers, contractors or of other with which the Corporation has a business relationship.
- 7. Consultant agrees that all files, memoranda, data, notes, records, drawings, charts, graphs, analyses, letters, reports, or other documents or similar items made or compiled by the Consultant, made available to the Consultant or otherwise coming into the Consultant's possession while engaged by the Corporation concerning any process, apparatus or products manufactured, sold, used, developed, investigated or considered by the Corporation concerning the CONFIDENTIAL INFORMATION or concerning any other business or activity of the Corporation shall remain at all times the property of the Corporation and shall be delivered to the Corporation upon termination of the Consultant's engagement with the Corporation or at any other time upon request.
- 8. The Consultant agrees that, during the term of the Consultant's engagement with the Corporation or upon termination thereof, and if requested by the Corporation to do so, the Consultant will sign an appropriate list of any and all CONFIDENTIAL INFORMATION of the Corporation of which the Consultant has knowledge or about which the Consultant has acquired information.

# ARTICLE II DUTIES AND NONCOMPETITION

- 1. Consultant's duties shall be those assigned agreed to between the Corporation from time-to-time, but shall include development of recruiting and Associate downline matters. Nothing contained in this agreement is intended to abrogate or affect the right of the Consultant to be paid in accordance with the compensation plan of the Corporation, as the same if from time-to-time in effect. The Consultant agrees that the Consultant will serve the Corporation diligently, faithfully and to the best of the Consultant's ability during the term of the Consultant's engagement with the Corporation, which shall be at the will of the Corporation, and which shall further be subject to the announced Policies and Procedures of the Corporation which shall from time-to-time be in effect. The Consultant shall devote reasonable time, efforts, ability and attention to the business of the Corporation and the performance of the Consultant's duties, understanding that the Consultant is an independent contractor for all purposes, including Federal Income Tax purposes.
- 2. Consultant acknowledges and understands that from time to time the Consultant's duties will require the Consultant to work at non-company locations. In such instance, the

Consultant agrees to comply with all of the policies, procedures and directives relevant to working at such non-company locations.

- 3. Consultant represents and admits that in the termination of the Consultant's engagement for any reason whatsoever, the Consultant's experiences and capabilities are such that the Consultant can obtain engagement in business engaged in other lines and/or of a different nature, and that the enforcement of a remedy by way of injunction will not prevent the Consultant from earning a livelihood.
- 4. Consultant acknowledges that the Consultant will receive special knowledge and specialized training from the Corporation, included in which is the CONFIDENTIAL INFORMATION identified in Article I above. The Consultant further acknowledges that training provided by the Corporation and the CONFIDENTIAL INFORMATION is valuable to the Corporation and, therefore, the Corporation's investment in the training and the protection and maintenance of the CONFIDENTIAL INFORMATION constitutes a legitimate interest to be protected by the Corporation by the covenant not to compete, set forth in Paragraph 5 of Article II of this Agreement.
- 5. The Consultant therefore agrees that during the term of the Consultant's engagement with the Corporation and for a period of one (1) year (or a shorter period with the written consent of the Corporation) after the Consultant shall cease to be engaged by the Corporation for any reason, the Consultant shall not, directly or indirectly engage in or solicit, as an owner, principal, director, officer, partner, consultant, engaged, distributor, agent of any business which competes with that of the Corporation in the United States of America. Additionally, the Consultant agrees that he/she shall not, without the prior written consent of the Corporation, for a period of one (1) year from the termination of the Consultant's engagement with the Corporation (or a shorter period with the written consent of the Corporation) in the United States of America:
- a. Solicit any current or prospective customer, Associate, partner, principal or investor of the Corporation;
- b. Directly or indirectly be engaged by, invest in, manage or engage in any business that is competitive with the business of the Corporation;
- c. Either as an individual, a partner, or a joint venturer, or in any other capacity whatsoever, directly or indirectly accept engagement with or render services to any business that markets products and services in competition with those marketed by or under development by the Corporation at the time of the termination of the Consultant's engagement with the company or offers its goods and/or services for sale via a sales mechanism such as multilevel marketing, network marketing or direct marketing.

As set forth above, the Consultant acknowledges that this noncompletion covenant is

ancillary to or a part of an otherwise enforceable agreement, such being the general agreement of Engagement and its related agreements concerning confidentiality and non-disclosure of CONFIDENTIAL INFORMATION and non-solicitation, at the time that this noncompetiton covenant is made, that the limitations as to time defined herein are reasonable and do not impose a greater restraint than is necessary to protect the goodwill or other business interests of the Corporation, that the limitations as to geographic area defined herein are reasonable and do not impose a greater restraint than is necessary to protect the goodwill or other business interests of the Corporation, and that the scope of activity to be restrained defined herein is reasonable and does not impose a greater restraint than is necessary to protect the good will or other business interests.

- 6. The Consultant agrees that during his engagement with the Corporation and for a period of one (1) year after termination of such engagement, he/she shall not, on his/her own behalf or on behalf of any other person or business entity, hire solicit, seek to hire or offer engagement to any person who now or later works for the Corporation, or who is a current or prospective employee of the Corporation. The Consultant further agrees that he will not in any other manner attempt, directly or indirectly, to influence, entice or encourage any person who now or later works for the Corporation, or who is a current or prospective employee of the Corporation, to leave the engagement of the Corporation during the operative term of this covenant of Non-Solicitation:
- a. Any corporation, partnership, association, agency, or business, engaged in the business of multi-level marketing, network marketing and/or direct selling or in the marketing, sales and distribution of dietary and nutritional supplement products in competition with the Corporation or any of its affiliates at the time the Consultant ceased to be engaged by the Corporation; or
- b. Any corporation, partnership, association, agency, or business, known to the Consultant to be an Associate or customer of the Corporation as of the date of the Consultant's cessation of engagement by the Corporation or with whom the Consultant had contact during, and by reason of, the Consultant's engagement by the Corporation.
- 7. Consultant agrees that in the highly competitive business in which the Corporation is engaged, personal contact is of primary importance in securing new and retaining present Associates and customers. The Consultant also agrees that the Corporation has a legitimate interest in maintaining its relationships with its Associates and customers and that it would be unfair for the Consultant to solicit the business of the Corporation's Associates and customers and exploit the personal relationships the Consultant develops with the Corporation's Associates and customers by virtue of the Consultant's access to the Corporation's customers as a result of the Consultant's engagement by the Corporation.
- 8. The Consultant therefore agrees that for a period of one (1) year after the  $\ensuremath{^{\circ}}$

Consultant shall cease to be engaged by the Corporation for any reason, the Consultant shall not solicit, in competition with the Corporation, the business of any person, company, firm, corporation, partnership, association, agency, or business, known to the Consultant to be an Associate and/or customer of the Corporation as of the date of the Consultant's cessation of engagement by the Corporation or with whom the Consultant had contact during, and by reason of, the Consultant's engagement by the Corporation.

- 8. The Consultant further agrees that for a period of one (1) year after the Consultant shall cease to be engaged by the Corporation for any reason, the Consultant will not, either directly or indirectly, through any person, firm, association or corporation with which the Consultant is now or may hereafter become associated, cause, influence or induce any present or future employee of the Corporation or its affiliates to leave the employ of the Corporation or its affiliates to accept engagement with the Consultant or with such person, firm, association, or corporation with whom the Consultant may then be affiliated.
- 10. The foregoing covenants not to compete shall not be held invalid or unenforceable because of the scope or the territory or actions subject thereto or restricted thereby, or the period of time within which such Agreement is operative; but award or decree in arbitration or any judgement of a court of competent jurisdiction, as the case may be, may define the maximum territory and actions subject thereto and restricted by this Article II and the period of time during which the Agreement is enforceable. Any alleged breach of other provisions of this Agreement asserted by the Consultant shall not be a defense for the Consultant to claims arising from the Corporation's enforcement of the provisions of this paragraph. Should the Consultant violate the noncompletion covenants of this Article II, then the period of time for these covenants shall automatically be extended for the period of time from which the Consultant began such violation until the Consultant permanently ceases such violation.
- 11. Irrespective of the term of engagement under this Agreement, and in consideration of the promises specified in Article II of this Agreement, the Corporation agrees as follows:
- a. To issue, within thirty days of the date of this Agreement, capital stock of the Corporation in an amount of 939,333 shares, it being agreed that notwithstanding any provision contained herein to the contrary, the Consultant agrees to be bound by the underwriting agreements or requirements by and between the Corporation and any Underwriter which might provide services to it in connection with any public offering of its capital stock ("Underwriter"). Further, should such Underwriter impose any restrictions upon the exercise, registration or other rights, concerning the of stock conferred hereby or which is otherwise owned by the Consultant, the Consultant agrees to further be bound by such requirements, limitations, restrictions, and/or agreements, as agreed to by the Corporation. You hereby appoint Mannatech (the Corporation) as your attorney-in-fact to execute all documents on your behalf concerning agreements offering the shares of stock which are conferred hereby, including, without limitation, those agreements with the Underwriter, referenced above; which the parties agree is of a value in excess of \$1,000.00.

- b. To provide specialized training as specified herein;
- c. To provide the Consultant with access to the Corporation's software and files, records, marketing procedures, processes, computer programs, compilations of information, records, Associate and client requirements, pricing techniques, lists, formulae, lists identifying Associates, partners, potential investors, methods of doing business and other CONFIDENTIAL INFORMATION which is regularly used in the operation of the business of the Corporation as is relevant to the Consultant's engagement in the opinion of the Corporation.
- 12. The Consultant agrees that the agreements, noncompetition agreements, nondisclosure agreements, and non-solicitation agreements set forth herein each constitute separate agreements, independently supported by good and adequate consideration and shall be severable from the other provisions of this Agreement and shall survive the Agreement. The existence of any claim or cause of action of the Consultant against the Corporation, whether predicated on this agreement or otherwise, shall not constitute a defense to the enforcement by the Corporation of the covenants and agreements of the Consultant contained in the noncompetiton, nondisclosure or the non-solicitation agreements. If a court of competent jurisdiction determines that any restriction in a clause or provision of this Agreement is void, illegal or unenforceable, the other clauses and provisions of this Agreement shall remain in full force and effect and the clauses and provisions that are determined to void, illegal or unenforceable shall be limited so that they shall remain in effect to the fullest extent permitted by law.
- 13. The Consultant will use his best efforts to ensure that no relative of his, nor any corporation or other entity or which he is a officer, principal, manager, director or shareholder or other affiliate, shall take any action that the Consultant could not take without violating any provision of this Agreement.
- 14. The Consultant recognizes and acknowledges that damages in the event of his breach of certain provisions of this Engagement Agreement would be inadequate, and the Consultant agrees that the Corporation, in addition to all other remedies it may have, shall have the right to injunctive relief via arbitration if there is a breach by the Consultant of any one or more of the provisions contained in Article II hereof.

Arbitration shall be the exclusive remedy for any and all disputes, claims or controversies, whether statutory, contractual or otherwise, between the Corporation and the Consultant concerning the Consultant's engagement or the termination thereof. In the event either party provides a Notice of Arbitration of Dispute to the other party, the Corporation and the Consultant agree to submit such dispute or controversy, whether statutory or otherwise, to an arbitrator selected from a panel of arbitrators of the American Arbitration Association located in Dallas, Texas. The effective rules of Commercial Arbitration of the American Arbitration Association shall control the Arbitration. In any arbitration proceeding conducted subject to these provisions, all statutes of limitations that would otherwise be applicable shall apply to any arbitration proceeding hereunder. In any arbitration proceeding conducted subject to these

provisions, the arbitrator is specifically empowered to decided any question pertaining to limitations, and may do so by documents or by a hearing, in his or her sole discretion. In this regard, the arbitrator may authorize the submission of pre-hearing motions similar to a motion to dismiss or for summary adjudication for the purposes of consideration this matter. The arbitrator's decision will be final and binding upon the parties. The parties further agree to abide by and perform any award rendered by the arbitrator. The prevailing party in such proceeding shall be entitled to record and have awarded its reasonable attorney's fees, in addition to any other relief to which it may be entitled. In rendering the award, the arbitrator shall state the reasons therefor, including any computations of actual damages or offsets, if applicable.

# ARTICLE III ASSIGNMENT OF INVENTIONS

- 1. The Consultant agrees to promptly disclose to the Corporation and Consultant hereby assigns to the Corporation or its designee, its assigns, successors or legal representatives, all, right, title and interest in and to any and all patents, formulae, inventions, processes, designs, software, firmware, circuitry, diagrams, copyrights, trade secrets, and any other proprietary information (collectively, the "Proprietary Information") whatsoever, conceived, developed or completed by the Consultant during the course of the Consultant's engagement with the Corporation, or using the Corporation's time, data, facilities and/or materials, provided the subject matter of the Proprietary Information is within the scope of the duties and responsibilities of one in the Consultant's position with the Corporation or occurs as a result of the Consultant's knowledge of a particular interest of the Corporation.
- 2. The Consultant agrees to assist the Corporation at any time during the Consultant's engagement with the Corporation, or after termination of the Consultant's engagement by the Corporation with reimbursement by the Corporation for all expenses incurred, in the preparation, execution, and delivery of any assignments, disclosures, patent applications, or papers within the scope and intent of this Agreement required to obtain patents or copyrights in the Proprietary Information in this or a foreign country and in connection with such other proceedings as may be necessary to vet title to the Proprietary Information in the Corporation, its assigns, successors, or legal representatives.

# ARTICLE IV MISCELLANEOUS

1. Termination. Nothing contained in this Agreement shall be construed as impairing the right of the Corporation to terminate the Consultant's engagement with the Corporation hereunder.

- 2. Obligations. The Consultant's obligations under this Agreement shall continue, survive and remain enforceable in accordance with the terms hereof, whether or not the Consultant's engagement with the Corporation shall be terminated voluntarily or involuntarily, with or without reason.
- 3. Enforcement. It is the express intention of the parties to this Agreement to comply with all laws applicable to the covenants and provisions contained in this Agreement. If any of the covenants contained in this Agreement are found to exceed in duration or scope those permitted by law, it is expressly agreed that such covenant may be reformed or modified by the, an award or decree of an arbitrator, or, if applicable, a final judgement of a court of competent jurisdiction or other lawful constituted authority, as the case may be, to reflect a lawful and enforceable duration or scope, and such covenant automatically shall be deemed to amended and modified so as to comply with the arbitration award, decree, judgment or order of such court or authority, as the case may be. If any one or more of the provisions contained herein shall for any reason be held invalid, illegal or unenforceable in any respect even after reformation, such invalidity, illegality or unenforceability shall not affect the enforceability or validity of any other provision contained in this Agreement, and this Agreement shall be construed as if such invalid, illegal, or unenforceable provisions had never been contained herein.
- 4. Waiver of Breach. The waiver by any party hereto of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach by any party.
- 5. Entire Agreement. This Agreement contains the entire agreement of the parties hereto. no modification or amendment of this Agreement may be made except by written agreement signed by both of the parties hereto.
- 6. Descriptive Headings. All headings, captions and arrangements used in this Agreement are intended solely for the convenience of the parties and shall not be deemed to limit, amplify or modify the terms of this Agreement nor affect the meaning thereof.
- 7. Governing Law. The substantive laws of the State of Texas, excluding any conflicts of law rule or principle that might otherwise refer to the substantive law of another jurisdiction, shall govern the interpretation, validity and effect of this Agreement without regard to the place for performance thereof. This Agreement has been executed and delivered by the parties hereto in Dallas County, Texas, and the Corporation and the Consultant agree that venue as to any action which might ensue after arbitration shall be proper with the state of federal courts in Dallas County, Texas to decide any matter relating to this Agreement.
- 8. Notices. Any notice or communication required or permitted hereby shall be in writing and shall be delivered personally, sent by prepaid telegram and followed with a confirming letter, or mailed by certified or registered mail, postage prepaid.

- (a) If to the Consultant, to:
   Ray Robbins
   2201 Ingleside
   Grand Prairie, TX 75050
- (b) If to the Corporation, to:

Mannatech, Incorporated 600 S. Royal Lane, Suite 200 Coppell, Texas 75019

or in the case of each party hereto, to such other address and to the attention of such other person as may have theretofore been specified in writing in like manner by such party to the other party. Each such notice or communication shall be deemed to have been given as of the date so delivered or at the expiration of the third business day following the date of the mailing.

- 9. Assignment. This Agreement shall insure to the benefit of and be binding upon the Corporation and the Consultant and their respective successors and assigns. The Consultant shall not be entitled to assign any rights or obligations hereunder.
- 10. Prior Agreement. This Agreement supersedes all prior agreements set forth in Compiled Exhibit "A" between the parties of any and every nature whatsoever, including agreements for additional compensation or benefits. All such prior agreements are null and void. Robbins is not, shall not be, and has not been a Vice President of the Corporation. He shall not, hereafter be designated as a "National Director of Sales and Marketing"; however the Corporation shall seek to determine a designation which is appropriate to his independent contractor status which is reasonably agreeable to the Consultant. The foregoing not with standing nothing contained in this provision shall be construed as to alter any compensation due to the Consultant as an Associate under the compensation plan of the Corporation, as the same is from time-to-time in effect, for the operation of his Mannatech business, or to in any way alter his agreement for compensation regarding the training of Associates which has been in effect since the inception of the business of the Corporation.
- 11. Consultant Acknowledgement. The Consultant affirms and attests by signing this Agreement that Consultant has read this Agreement before signing it and that the Consultant fully understands its purposes, terms, and provisions, which the Consultant hereby expressly acknowledges to be reasonable in all respects. The Consultant further acknowledges receipt of one (1) copy of this Agreement.

IN WITNESS WHEREOF, the parties hereto have signed this Agreement as of this19th day of August, 1997, and effective as of May 14, 1997.

Consultant:
/s/ Ray Robbins
Ray Robbins
Other entities to be bound: (List)

#### ACKNOWLEDGEMENT

THE STATE OF TEXAS

(S) (S) (S)

COUNTY OF DALLAS

BEFORE ME, the undersigned Notary Public, personally appeared RAY ROBBINS, and known to me to be the person whose name is subscribed to the foregoing instrument, and acknowledged to me that he executed the above instrument for the purposes and consideration expressed therein.

GIVEN UNDER MY HAND AND SEAL OF OFFICE on this 19th day of August, 1997.

/s/ Cheryl Anderson Notary Public, State of Texas

15